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HMGN proteins modulate chromatin structure by binding to chromatin, unfolding 
nucleosome arrays and altering the pattern of histone modifications.  HMGN3 is 
unique amongst the HMGN family as two splice variants are produced from the 
HMGN3 transcript.  HMGN3 was shown to regulate TNFα-induced expression of 
the murine chemokine gene CCL1 which is implicated in conditions such as 
asthma, atherosclerosis and cancer.  However, the mechanism by which HMGN3 
modulates gene expression was unknown.  This investigation studied the role of 
HMGN3 in modulating TNFα-induced expression of the mCCL1 gene, and 
identified changes in histone modifications associated with the mCCL1 gene 
during expression. 
Quantitative real-time PCR (QRT-PCR) results show that over-expression of 
HMGN3 in MEFs reduces mCCL1 induction by TNFα.  Chromatin 
immunoprecipitation (ChIP) assays show HMGN3 binds to the mCCL1 gene.  Peaks 
in Histone H3 lysine 14 acetylation (H3K14ac) coincide with peaks of HMGN3 
binding at the mCCL1 gene.  TNFα stimulation leads to decreased HMGN3 binding 
and this correlates with reduced H3K14ac at the mCCL1 gene.  This is 
reminiscent of a previous study that showed HMGN1 inhibits anisomycin-
stimulated fosB transcription.  Taken together, this shows that HMGN3 fine-
tunes TNFα-induced gene expression, and suggests it may be necessary to 
remove HMGN3 from the mCCL1 gene in order to get efficient transcription. 
mCCL1 is known to contain an inducible NF-B site.  TNFα induces the NF-B 
signalling cascade.  TNFα stimulation leads to the translocation of NF-B to the 
nucleus, as well as the kinase IKKα.  IKKα can directly phosphorylate H3S10 and 
enhance acetylation of H3K14 at NF-B regulated promoters.  p38 also induces 
phosphorylation of H3S10, which may improve access for NF-B to bind the NF-
B site. 
To investigate whether HMGN3 has an indirect role in regulating gene 
expression, NF-B and p38 luciferase assays were performed.  Results show that 
HMGN3 does not significantly affect either the NF-B or p38 signalling pathways.   
3 
Based on this work and other published data, the following model is proposed: 
HMGN3 binds mCCL1 chromatin, enhances acetylation of H3K14 as shown by 
ChIP, and may inhibit TNFα-induced H3S10 phosphorylation, possibly mediated 
by IKKα, thus inhibiting mCCL1 expression as shown by RNA data.  However, 
following TNFα stimulation, HMGN3 may become phosphorylated, possibly by 
IKKα or MSK1, reducing HMGN3 binding to chromatin as suggested by the ChIP 
results, enhancing the accessibility of H3S10 phosphorylation, possibly by IKKα.  
The reduced binding of HMGN3 may be necessary for efficient expression of the 
mCCL1 gene. 
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1 Introduction 
Eukaryotic cells contain DNA in complex with protein in the nucleus.  This 
complex, called chromatin, serves to compact and protect the DNA molecule 
and to control access of the cellular machinery to the genetic information.  
Compaction occurs on various levels (Figure 1) (Felsenfeld et al., 2003).  
Organisation begins with 146 base pairs of DNA wrapped around eight histone 
proteins, forming a complex called the nucleosome, an 11 nm structure (Luger 
et al., 1997).  Nucleosomal arrays fold to form two stack 30 nm chromatin fibres 
where short-range internucleosomal interactions occur (Dorigo et al., 2004).  
These fibres further compact into higher-order structures, however, the 
structural details remain to be determined.  These extended chromatin fibres 
form long-range fibre-fibre interactions that ultimately result in a highly 
organised and condensed chromosome as observed during mitosis with a light 
microscope. 
The hierarchy of condensed DNA must also permit access of cellular machinery 
to carry out essential processes such as transcription, replication and repair.  
The nucleosome lies at the heart of the condensed chromatin fibre and plays an 
important role in regulating access by facilitating reorganisation of chromatin.  
The nucleosome core particle consists of four proteins called histones: H2A, H2B, 
H3 and H4.  Two H3-H4 dimers form a central tetrameter to which two dimers of 
H2A-H2B interact with to form a histone octomer, the nucleosome (Luger et al., 
1997).  The histone N-terminal tails protrude from the nucleosome and are 
susceptible to trypsinolysis (Bohm and Crane-Robinson, 1984), hence only certain 
tail regions are visible in the X-ray studies by Luger et al.  The visible regions of 
the N-terminal tail of Histone H3 and H2B extend from the core particle and pass 
through the DNA minor groove.  Tails participate in forming the 30nm fibre and 
are important targets for post-translational modifications including acetylation, 
methylation and phosphorylation (Quina et al., 2006).  These histone 
modifications induce structural changes of the chromatin architecture by 
disrupting intra- and internucleosomal interactions and thus alter the 
accessibility of the cellular machinery to the DNA.  These modifications also 
provide recognition and binding sites for a host of transcription factors, proteins 
and other histone modifying enzymes.  Importantly, these epigenetic 
modifications change the chromatin architecture but do not alter the underlying





Figure 1  Packaging DNA 
Eukaryotic DNA is highly compacted into chromosomes.  DNA wrapped around nucleosomes 
forms an 11 nm, “beads on a string”, conformation.  This structure allows short-range 
internucleosomal interactions, resulting in a 30 nm fibre.  These fibres are further folded 
into higher-order structures, the details of which remain to be determined.  This produces a 
highly organised and condensed DNA fibre as depicted in the mitotic chromosome.  
Reprinted by permission from Macmillan Publishers Ltd: [Nature] (Felsenfeld, G. & Groudine, 
M. (2003), Nature 421: 448-453), copyright (2003). 
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genetic sequence.  This is important for regulating the expression of particular 
genes in different cell types, during the cell cycle and development. 
Certain chromatin regions termed heterochromatin are particularly condensed 
and transcriptionally inactive.  These regions are often tri-methylated at Histone 
H3K9, H3K27 and H4K20 (Pokholok et al., 2005; Barski et al., 2007; Schotta et 
al., 2004, Karachentsev et al., 2005).  In contrast, regions termed euchromatin 
are less condensed and more accessible to the cellular machinery involved with 
gene activation/transcription, replication and DNA repair.  The regions involved 
with gene activation/transcription are often tri-methylated at Histone H3K4, 
H3K36 and H3K79, while residues H3K9, H3K14 and Histone H4 are often 
acetylated (Pokholok et al., 2005; Koch et al., 2007; Roh et al., 2005).  
Acetylation is mediated by the histone acetyl transferase domain (HAT) present 
in multiprotein complexes such as PCAF/GCN5 which catalyse the transfer of an 
acetyl group from acetyl-coenzyme-A cofactor (acetyl Co-A) to a lysine residue.  
This transfer neutralises the basic charge of the lysine residue, destabilising and 
altering the histone-histone and histone-DNA interactions, thus causing both 
local and global changes in the chromatin fibre (Shogren-Knaak et al., 2006).  
Recognition of acetylated residues is mediated by bromodomain modules present 
in many chromatin-associated proteins and HATs.  Such modules are present in 
TAF TFII250, a large subunit of the TFIID complex important for transcription 
initiation.  In addition, the plant homeodomain of TAF3, a subunit of TFIID, is 
highly selective for and binds directly to H3K4me3 (Vermeulen et al., 2007).  
Therefore, although the nucleosome appears to package eukaryotic DNA into the 
confinements of the cell nucleus, it acts as a key regulator in the dynamics of 
DNA. 
These histone modifications are reversible.  Histone deacetylases (HDACs) such 
as Rpd3p (reduced potassium dependency-3 protein) catalyse the removal of 
acetyl groups from lysine residues, which generally correlates with gene 
repression, while methylated lysine residues can be demethylated by lysine 
demethylases.  Although the above modifications are often associated with a 
particular chromatin state (gene activation or repression), they have been 
associated with the other state (Berger, 2007).  It is therefore important to 
consider histone modifications in concert with each another as well as their 
genomic context to understand the biological activity. 
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In addition to the covalent modification of histones, non-histone proteins and 
multiprotein complexes mediate the remodelling and repositioning of 
nucleosomes for cellular processes requiring DNA access.  Current studies 
suggest nucleosome occupancy at promoters become depleted upon gene 
induction and replenished upon gene repression (Lee et al., 2004, Yuan et al., 
2005).  Nucleosome remodelling complexes such as SWI/SNF and RSC use ATP to 
alter histone-DNA interactions and may account for the observed nucleosome 
movement (Lusser and Kadonaga, 2003).  Also, other proteins such as 
Heterochromatin Protein 1 (HP1) which functions mainly in transcriptional 
repression (de Wit et al., 2007), and topoisomerases which function in the 
prevention, as well as the release of DNA superhelical torsion, all play a part in 
ensuring the tightly packed eukaryotic genome is readily accessible to support 
the cells needs. 
This project investigated the role of nucleosome binding protein HMGN3a in 
regulating gene expression.  HMGN proteins belong to a family of non-histone 
proteins known as high mobility group proteins (HMG) and participate in the 
dynamics of chromatin.  Based on a characteristic functional sequence, the HMG 
proteins are categorised into three subfamilies, these being HMGA, HMGB and 
HMGN (reviewed by Bianchi and Agresti, 2005).  HMGA proteins bind AT rich 
sequences in the minor groove of DNA and regulate transcription, while HMGB 
proteins contain HMG-box domains that bind the minor groove of DNA and bend 
the DNA, promoting binding of other proteins like TATA binding protein (TBP).  
HMGN proteins bind to the nucleosome and affect the compactness of chromatin 
(Ding et al., 1997).  Binding of HMGN is associated with open, transcriptionally 
active chromatin and is reviewed by Bustin (Birger et al., 2003, Bustin, 2001).  
Much of the information regarding the HMGN proteins has been gathered from 
studies of HMGN1 and HMGN2.  This investigation aimed to investigate the role 
of HMGN3 in regulating gene expression by studying the chemokine gene CCL1 in 
mouse embryonic fibroblast cells (MEFs).   
Previously, RNase protection assays showed CCL1, along with other chemokines, 
were expressed in MEFs (West, unpublished data).  To investigate whether the 
chromatin remodelling protein HMGN3a altered CCL1 expression, immortalised 
HMGN1-/- MEFs were engineered to express HMGN3a under the Tet-On system.  
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HMGN3a is expressed on addition of doxycycline.  Stimulating these MEF cells 
with cytokines such as TNFα induced expression of the chemokines identified by 
RNase protection, with the most reproducible results obtained for the expression 
of CCL1 following TNFα stimulation (West, unpublished data).  QRT-PCR analysis 
showed HMGN3a reduced the level of TNFα-induced CCL1 expression (West, 
unpublished data).  However, the mechanism by which HMGN3a mediates CCL1 
expression is unknown. 
To investigate the role of HMGN3 in regulating CCL1 gene expression, QRT-PCR 
was used to quantify CCL1 expression in the presence and absence of HMGN3, 
and chromatin immunoprecipitation (ChIP) to identify any histone modifications 
associated with HMGN3 across the CCL1 gene.  As HMGN proteins bind to 
nucleosomes and affect cellular processes such as repair, transcription and 
during development, altered expression may have profound consequences and 
lead to abnormalities and disease (Hock et al., 2007).  Further characterisation 
of the HMGN proteins will improve the understanding for the mechanisms 
involved in controlling DNA-dependent activities in the cell and the role non-
histone proteins play in regulating chromatin structure. 
1.1 The HMGN family and functional domains 
The HMGN proteins are approximately 10 kDa in size and found only in 
vertebrates.  The two founding members of the HMGN family, HMGN1 and 
HMGN2, were isolated 26 years ago (Johns, 1982).  More recently, HMGN3 and 
HMGN4 were discovered (West et al., 2001; Birger et al., 2001).  The HMGN 
proteins share highly conserved domains with one another and are highly 
conserved across species including mouse, frog, cow and human.  Each protein 
has the characteristic nucleosome-binding domain (NBD), a bipartite nuclear 
localisation signal (NLS), and a chromatin-unfolding domain (CHUD) (Figure 2, 
adapted from West et al., 2001) which is the least conserved among the 
domains.  The majority of information on these proteins has come from studies 
involving the founding members, but much of what has been learned is likely to 
be applicable to the other proteins owing to the high degree of homology, 
especially within the known functional domains.  For example, it has been shown 
homodimeric complexes of both HMGN1 or HMGN2 bind tightly to the 
nucleosome core particle (Sandeen et al., 1980), both proteins enhance 
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acetylation of Histone 3 Lysine 14 (H3K14) (Ueda et al., 2006), and both reduce 
the compactness of the chromatin structure (Trieschmann et al., 1995). 












N1  PKRKV-SSAEG-----AAKEEPKRRSARLSAKP-PAKVEAKPKKAAAK-DKSSDKKVQT 
N2  PKRKAEGDAKG-DKAKV-KDEPQRRSARLSAKPAPPKPEPKPKKAPAK-----KGEKVP 
N4  PKRKAKGDAKG-DKAKV-KDEPQRRSARLSAKPAPPKPEPRPKKASAK-----KGEKLP 
 
 
    NLS2                    CHUD 
 
N3a KGKKEEKQEAGKEGTA-------PSENGETKAEEAQKTESVDNEGE    98 
N3b KGKKEEKQEAGKEGTEN                                 76 
N1  KGKRGAKGK-QAEVANQETKEDLPAENGETKTEESPASDEAGEKEAKSD 99 
N2  KGKKG-KADAGKEGNN-------PAENGDAKTDQAQKAEGAGDAK     89 
N4  KGRKG-KADAGKDGNN-------PAKNRDASTLQSQKAEGTGDAK     89 
 
Figure 2  Amino acid sequence alignment of human HMGN proteins 
Conserved residues between HMGN members are in bold.  Residues conserved between three 
of the full-length transcripts are underlined.  The two nuclear localisation signals (NLS1 and 
NLS2), the nucleosome-binding domain (NBD) and chromatin-unfolding domain (CHUD) are 
highlighted in grey and indicated above the alignments.  The total number of amino acids for 
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1.2 HMGN genes 
HMGN1, 2, 3 and 4 are present at positions 21q22.3, 1p36.1, 6q27, and 6p21.3 in 
humans, with the genes spanning 6.8, 3.5, 32 and 2kb respectively (Landsman et 
al., 1989; Popescu et al., 1990; West et al., 2001; Birger et al., 2001).  The 
location of HMGN1, 2, and 3 in mouse lie at positions 16 69.8 cM, 4 62.2 cM and 
9 E3.1, while further analysis is required to locate the HMGN4 gene.  The genes 
for HMGN1, 2 and 3 have six exons, while HMGN4 is intronless.  HMGN3 is much 
larger than the other HMGN genes and is largely due to intron I of HMGN3 
spanning 18kb (West et al., 2001). 
1.3 HMGN3 transcription 
The HMGN3 transcript is unique amongst the HMGN family in that it undergoes 
alternative splicing.  This arises due to a 41-nucleotide deletion after the codon 
for glycine 72, causing a frameshift.  As a result, the following codons encode 
Thr-Glu-Asn-STOP.  HMGN3a denotes the full-length protein while HMGN3b the 
truncated protein.  Although HMGN3a and HMGN3b are identical in sequence (to 
glycine 72), HMGN3b lacks the majority of the CHUD present in HMGN3a (Figure 
2).  This may have important implications in protein function, for both isoforms 
retain the capacity to associate with nucleosomes through the NBD, but only 
HMGN3a retains the functional CHUD.  As such, HMGN3b may function as a 
competitive inhibitor to HMGN3a (or other family members) through nucleosome 
occupancy, or indirectly through dimer formation (HMGN3a-HMGN3b) as dimers 
exist between two HMGN1 or two HMGN2 proteins (Sandeen et al., 1980). 
1.4 Nucleosome binding domain 
The highly conserved NBD is 30 amino acids in length and positively charged.  
The domain is lysine and proline rich (Figure 2).  The NBD is the major 
determinant for HMGN protein interaction with the nucleosome, although FRAP 
analysis shows the C-terminal region contributes too (Ueda et al., 2008).  
Embedded within the NBD is the conserved sequence RRSARLSA, residues 22-29 
in HMGN2 (Figure 2).  Mutational analysis of this sequence indicates four amino 
acids to be essential to permit nucleosomal binding, these being R22 S24 R26 L27 in 
HMGN2 (Ueda et al., 2008).  S24 of HMGN2 specifically binds to Histone H3, 
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indicating the NBD lies very close to Histone H3.  The authors also report wild 
type HMGN2 has a similar affinity for purified DNA (deproteinised DNA) as a 
HMGN2-S24, S28 mutant.  However, the mutant has a significantly decreased 
affinity for nucleosome core particles than wild type, suggesting HMGN proteins 
may be able to interact with chromatin without occupying nucleosomes (see 
Section 1.9). 
1.5 Chromatin unfolding domain 
Binding of the NBD to the nucleosome positions the C-terminal domain within 
the vicinity of the N-terminal tail of Histone H3 (Trieschmann et al., 1998).  
Crosslinking of HMGN1 to nucleosome-DNA complexes showed the CHUD targets 
the N-terminal tail of Histone H3, thus, being ideally placed to interact with the 
tail domain of Histone H3.  Such interaction could induce structural changes in 
the chromatin fibre directly by disrupting nucleosome-DNA or nucleosome-
nucleosome interactions, and/or alternatively, through altering the ability of 
histone enzymes to modify the histone tails.  Therefore, HMGN binding to 
nucleosomes may affect chromatin structure both at the individual nucleosome 
level and, in doing so, at the chromatin fibre level too. 
With the exception of HMGN3b, all HMGN CHUDs are negatively charged.  
HMGN3a has the greatest negative charge of negative eight.  The CHUD is 
responsible for transcriptional enhancement by HMGN proteins (Trieschmann et 
al., 1995) and therefore HMGN3b may have a reduced impact on transcription 
(see Section 1.10). 
1.6 Regulation and expression of HMGN proteins 
Studies on the regulation and expression of HMGN proteins to date have focused 
on HMGN1, 2 and 3.  These genes appear like most other housekeeping genes in 
that they have CpG islands that span the promoter region.  However, there is no 
significant common regulatory element amongst the HMGN genes.  A CCAAT 
sequence that binds the NF-Y transcription factor is present on HMGN1, 2 and 3, 
although this is found in many promoters (West et al., 2001).  A TATA box is 
present for HMGN2 and 4, but not HMGN1 or 2, while SP1 sites are present for 
HMGN1, 2 and 4 but absent from HMGN3.  The absence of conserved 
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transcription factor binding sites amongst the HMGN genes suggests gene 
expression is regulated differently.  This may account for the tissue specific 
expression profiles. 
HMGN3 expression levels vary between tissues and between the same tissue 
types from different species (West et al., 2001).  HMGN mRNA levels within any 
particular tissue generally correlates with the level of protein.  Human HMGN3 
mRNA levels are highest in the pancreas, pituitary and heart while mice have 
highest levels in eye, brain and prostate.  In contrast, human brain and prostate 
have low levels of HMGN3 and mouse has low levels in pancreas.  Large 
differences in the level of HMGN3 between human and mouse brain may be due 
to the section of brain tissue analysed, as different regions of the brain had 
different levels of HMGN3 protein (Ito and Bustin, 2002).  Nevertheless, between 
species many tissues have similar levels of mRNA expression, including lung, 
thyroid and spleen. 
HMGN3b (Trip7) has a developmental role in Xenopus laevis (Amano et al., 
2002).  In tissues undergoing metamorphosis, HMGN3b is expressed and up-
regulated by Thyroid hormone, with the exception of tissues that undergo 
complete resorption.  HMGN3b interacts with the thyroid hormone receptor and 
in the presence of thyroid hormone promotes transcription from chromatin 
templates.  Pre- and post-metamorphosis, HMGN3 expression is low, but at the 
climax of metamorphosis, HMGN3 levels are high. 
In a similar theme, during embryogenesis, expression of HMGN1 is progressively 
down-regulated (Furusawa et al., 2006).  Higher levels of HMGN1 expression 
occur in 7-day-old mouse embryos than in 11-, 15-, and 18-day-old embryos.  
HMGN1 expression is significantly decreased in differentiated tissues, although 
cells poised for renewal such as the basal layer of the stomach lining remain 
high.  Similarly, HMGN2 is down-regulated in differentiated cells, but abundant 
in those undergoing active differentiation (Lehtonen and Lehtonen, 2001).  This 
provides strong support that HMGN proteins play a significant role in 
differentiation and development.  As has been suggested, this is likely to involve 
chromatin interaction, as re-expression of HMGN1 in HMGN1 knock out mice 
restores the rate of differentiation (of mesenchymal cells), whereas a HMGN1 
mutant unable to bind chromatin, does not (Furusawa et al., 2006). 
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1.7 Targeting of HMGN proteins to nucleosomes 
Although it is known HMGN proteins bind to nucleosomes, it is unclear as to how 
targeting is accomplished as studies with HMGN1, 2 and 3 show the proteins have 
no preferential binding sequence (Shirakawa et al., 2000; West et al., 2001).  
HMGN1 and 2 have a slight preference for nucleosomes in DNA regions depleted 
of nucleotides CG and enriched in AT and TA, while methylation of CG sequences 
has no effect on HMGN binding (Shirakawa et al., 2000).  However, based on the 
affinity constants of HMGN proteins, this on its own is deemed insufficient to 
constitute a major factor in HMGN targeting. 
HMGN proteins compete with linker Histone H1 for nucleosome binding sites 
(Catez et al., 2002).  Histone H1 proteins help stabilise chromatin at the 
individual nucleosome level and at the 30 nm fibre (Figure 1).  Like HMGN 
proteins, these are dynamic and reside longer on than off the chromatin fibre. 
(Phair et al., 2004).  HMGN proteins compete for binding sites but do not 
displace bound Histone H1 from chromatin (Ueda et al., 2008). 
1.8 Gene regulation by HMGN proteins 
The HMGN proteins bind transiently to chromatin.  Moving rapidly throughout the 
nucleus (Catez et al, 2003), the proteins “hop” on and off the chromatin fibre, 
spending longer on than off (Phair et al., 2004).  In some cases, HMGN proteins 
may reach their targets in complex with other proteins.  Lim et al., (2002) 
identified five HMGN1 and three HMGN2 containing complexes.  More recently, 
HMGN2 was identified in complex with the paired-like homeodomain 
transcription factor 2 (PITX2) (Amen et al., 2008).  This prevents PITX2 from 
binding DNA.  However, in the presence of Wnt signalling, B-catenin translocates 
into the nucleus and forms a complex with HMGN2-PITX2.  This enables DNA 
binding of PITX2, activating transcription.  In the absence of Wnt signalling, B-
catenin is degraded in the cytoplasm, preventing the HMGN2-PITX2 complex 
binding its DNA target.  This mechanism provides one possibility of how different 
HMGN family members are targeted to specific chromatin sites to regulate 
individual genes.  Further, HMGN proteins are known to increase the efficiency 
of transcription initiation and in promoting transcriptional elongation by 
reducing the compaction of the chromatin fibre (Paranjape et al., 1995; Ding et 
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al., 1994).  Therefore, HMGN proteins may fine-tune the targeting of 
transcription factors. 
1.9 Cell cycle dependent localisation of HMGN proteins 
The intranuclear distribution of HMGN proteins is cell cycle dependent.  Several 
residues of the HMGN proteins undergo covalent modification including 
acetylation (Bergel et al., 2000; Herrera et al., 1999) and phosphorylation (Louie 
et al., 2000; Lim et al., 2004).  During interphase, HMGN proteins are associated 
with chromatin as well as scattered throughout the nucleus.  However, during 
the mitotic phase, the NBD undergoes phosphorylation, preventing nucleosome 
binding (Hock et al., 1998; Prymakowska-Bosak et al., 2001) and HMGN proteins 
are found scattered throughout the intracellular space as separate entities from 
chromatin.  A decrease in the level of phosphorylated HMGN in the cytoplasm 
occurs with the progression of telophase, with a concomitant increase in non-
phosphorylated HMGN bound to DNA in the nucleus (Hock et al., 1998; 
Prymakowska-Bosak et al., 2002). 
However, more recently fluorescently labelled HMGN proteins were found 
associated with mitotic chromosomes (Pallier et al., 2003).  This contradiction 
has been investigated (Cherukuri et al., 2008).  HMGN1 residues S20 and S24 are 
critical for the specific nucleosome binding activity during interphase 
(Prymakowska-Bosak et al., 2001); however, mutation to glutamic acid abolishes 
this.  Pallier and co-workers show the mutant protein is in fact able to bind DNA 
during the mitotic phase, but this interaction is weaker and the protein unable 
to form specific complexes with nucleosomes, in contrast to interphase.  Thus, 
this study established the NBD is not required for DNA binding during the mitotic 
phase (Cherukuri et al., 2008). 
The different cellular distributions of phosphorylated and unphosphorylated 
HMGN proteins during the interphase/mitotic transition may be mediated by 
14.3.3 proteins, a class of protein involved in cellular targeting (Prymakowska-
Bosak et al., 2002).  The phosphorylated HMGN NBD promotes binding to 14.3.3 
proteins, impairing nuclear import of the protein.  The proteins reside in the 
cytoplasm until the nuclear membrane reforms, thus reducing the level of 
chromatin bound HMGN during mitosis.  Conceivably this is important to prevent 
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unwanted and unnecessary DNA transcription, as well as to promote a more 
condensed chromatin structure.  This may enhance the ease at which the newly 
synthesised chromosomes are separated by the microtubules and may reduce the 
chance of erroneous events occurring such as chromosome breakages and 
translocations. 
Once the nuclear membrane reforms the HMGN proteins re-associate with 
chromatin, mediated by active transport (Hock et al., 1998).  In late telophase, 
the HMGN proteins in a complex containing importin-α transport the proteins 
through the nuclear pores into the nucleus (Hock et al., 1998).  The proteins are 
then ideally placed to re-associate with the chromosomes. 
1.10 Gene regulation by HMGN3 
HMGN3 gene regulation studies show both HMGN3a and HMGN3b participate in 
the up and down regulation of gene expression in various cell types (West et al., 
2004a).  Of the genes studied, none are up-regulated by both isoforms, although 
some are down-regulated by either.  HMGN3a increases expression of the glycine 
transporter 1 gene (Glyt1), a gene expressed in the brain, by as much as 19-fold, 
while HMGN3b has a smaller effect.  This is in agreement with studies in which 
mutant HMGN proteins lacking portions of their C-terminal domains conferred 
reduced transcription rates over full-length HMGN proteins.  As the HMGN3b 
sequence is identical to the corresponding HMGN3a amino acid sequence (Figure 
2), nucleosome binding via the NBD may induce a structural change in the 
chromatin fibre favouring an increase in transcription.  However, HMGN3a may 
enhance the level of transcription further than HMGN3b by inducing histone 
modifications that favour a more stable chromatin conformation than that alone 
of HMGN3b, possibly through the CHUD interacting with the Histone H3 N-
terminal tail, similar to that of HMGN1 (Section 1.5, Trieschmann et al., 1998). 
HMGN3 proteins are enriched around a 3.5 kb region of the Glyt1 transcription 
start site, suggesting HMGN3 may play a role in enhancing transcription.  HMGN3 
proteins may bind some of the nucleosomes via their NBD in this 3.5 kb region 
and make available previously inaccessible nucleosomes.  This may allow access 
of other histone modifying enzymes that may even be recruited and travel along 
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with polymerase II (Barski et al., 2007), thus enhancing the efficiency of 
elongation by RNA polymerase. 
As mentioned earlier, although HMGN3b enhances transcription to a lesser 
extent than HMGN3a, it can interact with the thyroid hormone receptor to 
promote thyroid-hormone-dependent transcription (Amano et al., 2002).  
Therefore, although similarity exists between HMGN proteins, each may interact 
different with the same transcription factors (or different factors), conferring 
different properties on the DNA sequence they regulate.  HMGN3a may act 
cooperatively with a transcription factor at the Glyt1 gene, while HMGN3b acts 
less so. 
1.11 Covalent post-translational modifications 
Nucleosomal bound HMGN1 impedes MSK1 (mitogen-and stress-activated protein 
kinase) and RSK2 (ribosomal S6 kinase) mediated phosphorylation of Histone H3 
serine 10 (Lim et al., 2004).  H3S10ph is correlated with transcriptionally 
inactive, condensed mitotic chromosomes but also with actively transcribed 
genes during interphase and during the transient expression of immediate early 
(IE) genes (Johansen and Johansen, 2006).  IE genes are rapidly expressed 
following stimulation with growth factors, cytokines or pharmacological 
compounds such as anisomycin (reviewed by Thomson et al., 1999a).  HMGN1 S6 
and H3S10 undergo rapid and transient phosphorylation in cells induced with 
anisomycin, an effect termed the nucleosomal response (Thomson et al., 
1999b).  This is due to the highly efficient phosphorylation by MSK1 and to a 
lesser extent RSK2 (Thomson et al., 1999b; Lim et al., 2004).  MSK1 also targets 
HMGN1 NBD at S20 and S24 (Lim et al., 2004).  When these residues are 
phosphorylated, HMGN is unable to bind the nucleosome (Figure 3A) 
(Prymakowski-Bosak et al., 2001).  During the nucleosomal response, 
phosphorylation of HMGN1 S20 and S24 precedes that of S6.  This reduces 
nucleosome binding of HMGN1, allowing access of MSK1 to phosphorylate Histone 
H3S10 and S28 (Lim et al., 2004). 
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                = Phosphorylated   CHUD = Chromatin Unfolding Domain 
 
Figure 3  HMGN1 and HMGN2 modulate post-translational modifications of the nucleosome. 
(A)  HMGN1, but not HMGN2, inhibits MSK1 and RSK2 phosphorylation of Histone H3S10 and 
H3S28.  Upon anisomycin stimulation, MSK1 phosphorylates HMGN1 serine residues S6, S20 
and S24, step 1.  HMGN1 loses interaction with the nucleosome, allowing MSK1 to 
phosphorylate Histone H3S10 and H3S28.  Inhibition of MSK1 by HMGN1 is conferred by 
nuclear localisation signal 2 (NLS2).  (B) HMGN2 enhances PCAF mediated acetylation of 
Histone H3K14.  Enhancement is associated with the chromatin-unfolding domain (CHUD). 
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Unlike HMGN1, HMGN2 does not inhibit phosphorylation of H3S10 and S28 by 
MSK1 despite having a similar affinity constant for nucleosomes, indicating that 
binding alone is insufficient (Ueda et al., 2006; Shirakawa et al., 2000).  
Inhibition localises to residues 42-73 of HMGN1 (Ueda et al., 2006). 
HMGN2 does, however, enhance PCAF-mediated acetylation of H3K14 3.5-fold, 
compared with a significantly less 2-fold increase for HMGN1 (Ueda et al., 2006, 
Lim et al., 2005).  Enhancement localises to residues 68-89 of HMGN2 which lie 
within the CHUD (Figure 2).   
The CHUD motifs of HMGN1 and 2 have net negative charges of two and seven.  
The seven amino acid sequence conserved between HMGN2, 3 and 4 is less 
conserved for HMGN1 (Figure 2, HMGN1 residues 55-64) and may account for the 
different acetylation enhancements.  As the HMGN3 isoforms have different 
overall C-termini charges they are likely to have different functions in chromatin 
modification. 
1.12 Further HMGN functions   
Incorporation of HMGN2 into chromatin during chromatin assembly stimulates 
replication efficiency of DNA (Vestner et al., 1998).  HMGN proteins are also 
involved in DNA repair.  HMGN1 null mice appear normal but are hypersensitive 
to UV-B irradiation and have higher incidence of sporadic tumours (Birger et al., 
2003, West et al., 2004b).  It is likely HMGN1 opens up the chromatin structure, 
allowing the nucleotide excision repair machinery access to the site of DNA 
damage.  The possibility HMGN1 affects remodelling of chromatin by the 
SWI/SNF complex proved negative, with HMGN1 having no apparent effect on 
the rate of remodelling (Hill et al., 2005). 
1.13 Alternative and diverse roles of HMGN 
HMGN proteins are typically located within the nucleus, however, recently 
HMGN2 was found in the cytoplasm of IL-2 stimulated mononuclear leukocytes 
(Feng et al., 2005).  The NBD of HMGN2 was found to have strong antimicrobial 
properties to E. coli ML-35p.  Thus, HMGN proteins may have roles in addition to 
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regulating chromatin structure; they may participate in immune defence, 
possibly through combat with invading bacteria. 
The NBD has also been found to preferentially target tumour cells (Porkka et al., 
2002).  The NBD of HMGN2 binds to and accumulates in the nuclei of mice 
bearing either HL-60 (human myeloid leukaemia cell line) or MDA-MB-435 (human 
breast carcinoma cell line) tumours, and in tumour endothelial cells.  Nucleolin 
is responsible for shuttling the NBD from the cell surface into the nucleus 
(Christian et al., 2003).  Nucleolin is expressed mainly on the surface of cells 
undergoing proliferation and on angiogenic endothelium. 
In one other, more recent study, a recombinant chimeric toxin using the NBD of 
HMGN2 and pseudomonas exotoxin domain III (PE) was generated (Xiong et al., 
2008).  PE is an exotoxin derived from Pseudomonas areuginosa that kills animal 
cells by inhibition of protein synthesis.  In vitro, the cytotoxicity of the chimeric 
protein has a greater effect on HeLa cells than on normal human cervical 
epithelial cells, producing an increased mortality rate.  Higher levels of the 
chimeric protein labelled with fluorescein isothiocyanate (FITC) were found in 
HeLa cells (31% of cells fluorescent) compared with almost no fluorescence in 
human cervical epithelial cells.  In vivo experiments on mice bearing HeLa 
tumours treated with the chimeric protein show inhibition of tumour growth, 
large areas of necrosis and some apoptosis, with no obvious abnormalities in the 
other tissues or organs. 
The studies by Porkka and Xiong et al., provide evidence that HMGN proteins, or 
at least the NBD sequence that is characteristic of the HMGN proteins, have 
alternative roles from nucleosome binding.  Further characterisation of HMGN 
proteins will enhance our understanding of gene regulation and chromatin 
dynamics.  It may improve our ability to combat disease such as cancer by the 
direct delivery of anticancer compounds to cancerous cells using the NBD as a 
carrier.  Alternatively, one family member of the HMGN proteins may be solely 
responsible for the up-regulation of an oncogene or down-regulation of tumour 
suppressor genes.  Thus, it may be possible to target uniquely this member by, 
for example RNAi (Hill and Imbalzano, 2006), to suppress the undesirable effects 
if the other HMGN proteins can compensate for the normal regulation within 
healthy cells (HMGN1-/- mice display only a mild phenotype (Birger et al, 2003)). 
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1.14 Summary of HMGN proteins 
HMGN proteins are non-histone proteins found only in vertebrates.  These 
proteins bind to nucleosomes and DNA, reduce the compactness of chromatin 
and enhance transcription and replication from chromatin templates.  They 
affect histone modifications, and in vivo, are highly dynamic and compete with 
Histone H1 for nucleosome binding sites.  Cellular localisation of HMGN proteins 
are cell cycle dependent and they form complexes with other proteins.  The NBD 
has the potential for use as a carrier to deliver drugs to cancerous cells.
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2 CCL1 
2.1 Introduction to chemokines 
The chemokines form a family of chemotactic cytokines, best known for their 
role in regulating the migration of different cells in the body.  Around 50 
chemokines have been identified in humans and most if not all are thought to 
have arisen from gene duplication and diversification.  As a result, many are 
found clustered in defined chromosome regions (Zlotnik et al., 2006 and 
Colobran et al., 2007).  The latest nomenclature revision of chemokines and 
chemokine receptors (Zlotnik and Yoshie, 2000) categorises chemokines into four 
subfamilies based on the spacing of the first two cysteine residues, and the 
receptors are named according to the subfamily of chemokine that binds.  Thus, 
the cytokine subfamilies are CC CXC XC CX3C.  Recently a fifth subfamily was 
discovered in zebrafish and termed CX (Nomiyama et al., 2008).  mCCL1 belongs 
to the CC subfamily. 
2.2 CCL1 gene structure 
This project focuses on how HMGN3 participates in the regulation of T-Cell 
Activation gene 3 (TCA3).  TCA3 (referred from here on in as mCCL1) is a murine 
chemokine originally isolated from a cDNA library derived from a T-cell clone 
(Burd et al., 1987).  The human homologue hCCL1 (also known as I-309) was 
identified soon after (Miller et al., 1989).  mCCL1 is located on mouse 
chromosome 11 47.32 cM and hCCL1 on human chromosome 17q11.2 (Burd et 
al., 1987; Miller et al., 1990).  These genes are found clustered with the 
majority of other CC chemokines.  A common theme amongst CC chemokines is 
that they have three exons with highly conserved intron/exon boundaries (Miller 
et al., 1990, Zlotnik et al., 2006).  This suggests the genes evolved from a 
common ancestor.  Human and mouse CCL1 share 55% nucleotide homology 
(Miller et al., 1989) although greater homology exists 5’ to the transcription 
start site (TSS).  mCCL1 region (-320 to -76) and hCCL1 region (-314 to -91) share 
69% homology (Miller et al., 1990) and contain various conserved sequence 
motifs.  These include a palindromic NF-B, E1A enhancer core and a PU.1 
transcription factor binding site.  In addition to these, hCCL1 contains an Ig H 
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chain enhancer octamer (-455 to -448) and a µE5 element (-384 to -376).  The 
NF-B element is important for regulating mCCL1 induction (Oh and Metcalfe, 
1994) but further experiments are required to show whether any of the other 
elements participate in regulating gene expression.  Initiation of mCCL1 
transcription requires two intracellular signals for the efficient expression in T-
cells (Wilson et al., 1988).  These signals are transduced through the T-cell 
receptor (TCR) complex, and like other lymphokine genes, this causes both an 
increase in intracellular calcium concentration and activation of protein kinase C 
(PKC). 
2.2.1 NF-B element 
The region extending 82 nucleotides upstream of the mCCL1 TSS induces 
reporter gene expression that is further enhanced by the region extending to -
1342 (Oh et al., 1997).  An inducible NF-B element lies at position -194 to -185.  
Activation of the NF-B pathway by tumour necrosis factor alpha (TNFα) is well 
established and regulates the expression of other chemokines too.  The TNF-
induced activation of the NF-B signalling pathway involves TNF binding the 
transmembrane cell surface receptor TNF-R1, releasing the inhibitor protein 
SODD from TNF-R1’s intracellular domain (Figure 4).  This allows TRADD to 
associate with TNF-R1 and recruit RIP, TRAF2 and FADD.  Other proteins are 
recruited here including IKK.  IKK consists of two kinases, IKKα and IKKβ, as well 
as a regulatory subunit IKKγ (reviewed by Ghosh and Hayden, 2008).  Stimulation 
with TNFα activates IKKβ phosphorylation of IB, leading to the degradation of 
IκB and exposure of the NLS on NF-B.  NF-B is free to translocate from the 
cytoplasm to the nucleus where it can bind NF-B elements and stimulate 
transcription.  However, IKKα translocates to the nucleus and directly 
phosphorylates H3S10 and enhances H3K14ac (Anest et al., 2003; Yamamoto et 
al., 2003).  CBP and IKKα are recruited to NF-B dependent promoters following 
TNFα stimulation and CBP acetylates H3K14. 



















































Legend: TNFα, tumour necrosis factor α;  TNF-R1, TNFα-receptor 1;  SODD = silencer of death 
domain;  TRADD, TNF receptor-associated death domain;  RIP, receptor-interacting protein;  
TRAF2, TNF-R-associated factor 2;  FADD, Fas-associated death domain;  IB, inhibitor of IB;  
IKK, IB kinase;  NF-B, nuclear factor B;  NLS, nuclear localisation signal;  
    , phosphorylated;    , ubiquitinated. 
Figure 4  TNFα induction of mCCL1 expression through the NF-B pathway 
The binding of TNFα to its transmembrane protein receptor induces the release of the 
inhibitor protein SODD from the intracellular surface of the transmembrane protein and the 
binding of TRADD.  This leads to the recruitment of other intracellular proteins including IKK.  
In the inactive state, NF-B is sequestered in the cytoplasm by IB.  IB bound to NF-B 
undergoes phosphorylation by IKK, leading to ubiquitination and degradation of IB, whilst 
exposing the NLS on NF-B.  Translocation of NF-B to the nucleus and binding to the NF-B 
site induces transcription. 
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TNFα also stimulates the p38 pathway (Beyaert et al., 1996).  p38 induces H3S10 
phosphorylation at a subset of NF-B dependent chemokine genes (Saccani et 
al., 2002).  Translocation of NF-B into the nucleus binds and activates genes 
that constitutively expose NF-B binding sites.  p38 is thought to promote 
chromatin remodelling through phosphorylation of H3S10, thus, exposing less 
accessible NF-B binding sites.  This way, depending on the magnitude of the 
stimulus (e.g. TNFα), the immune cell controls the level of response (e.g. 
recruitment of other immune cells - Section 2.3). 
2.2.2 Negative regulatory elements (NRE) 
Extending further from the TSS lie separate negative regulatory elements (NRE) 
(Oh et al., 1997).  These exist between -2057 and -1342 (Figure 4).  This region 
can be subdivided into NRE-1 (-2057 to -1493) and NRE-2 (-1492 to -1342) based 
on a HindIII cleavage site.  When placed in a reporter construct both elements 
inhibit CAT transcription in a distance (from TSS)-independent manner, but only 
NRE-1 is orientation-independent as NRE-2 only inhibited transcription when 
placed in the 5’-3’ orientation.  Either NRE inhibits transcription from CD20-
promoter constructs, indicating a redundancy of NREs within the CCL1 promoter. 
Within NRE-1 lie two sequences similar to the IL-4 silencer motif and are termed 
NRE-1a and NRE-1b.  Only NRE-1a has been characterised and is essential for the 
regulatory activity of NRE1; however, it does not bind the protein that interacts 
with the IL-4 silencer sequence.  Therefore, a novel protein may bind and confer 
the negative regulatory properties of NRE-1a. 
Within NRE-2 lies a sequence similar to the lysozyme silencer motif, termed NRE-
2a, and a sequence matching the silencer sequence of the αIIb integrin gene, 
termed NRE-2b.  NRE-2b is deemed necessary but not sufficient to confer the 
negative regulatory activity of NRE-2, and it may bind the same protein that 
interacts with the IL-4 silencer sequence though further purification of the 
identified protein complexes are required.  NRE-2a does not bind to the same 
protein that interacts with the lysozyme silencer motif but may act 
synergistically with NRE-2b to confer negative regulatory activity. 
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To summarise the regulatory mCCL1 promoter sequences, the region extending 
1342bp upstream from the TSS enhances transcription, while the region 
extending upstream from 1342 to 2057bp inhibits transcription (Figure 4). 
2.3 CCL1 expression and secretion  
mCCL1 is expressed in activated T helper 1 (TH1), T helper 2 (TH2), cytolytic T 
lymphocytes (CTL), natural killer T cells (NKT) and mast cells (Kennedy et al., 
2000; Wilson et al., 1988).  mCCL1 directly induces chemotaxis of 
monocytes/macrophages and neutrophils (Doyle and Murphy, 1999; Miller and 
Krangel, 1992; Luo et al., 1994), while the human homologue hCCL1 is secreted 
by and is chemotactic for monocytes and T lymphocytes (Selvan et al., 1997; 
Miller et al., 1989; Miller and Krangle, 1992; D’Ambrosio et al., 1998), but not 
neutrophils (Miller et al., 1992).  These differences/discrepancies may be due to 
different signalling mechanisms in mouse and human cells or due to 
experimental techniques.  Initial studies showed mCCL1 was unable to induce 
chemotaxis of eosinophils (Doyle and Murphy, 1999).  However, IL-5 
overexpressing eosinophils elicited with TNFα (20 ng/ml) or high IL-4 
concentration (20 ng/ml), induced migration and de novo CCR8 mRNA 
expression, the receptor for CCL1 (Oliveira et al., 2002). 
2.4 CCL1 binds CCR8 
mCCL1 and hCCL1 share 42% amino acid homology (Miller et al., 1989).  The 
genes produce 92 and 96 amino acid proteins respectively, but the proteins 
contain a secretory signal sequence that is cleaved from the N terminus upon 
release (Burd et al., 1987).  The peptide undergoes asparagine-linked 
glycosylation that increases the molecular mass of the non-glycosylated peptide 
from 8 kDa to approximately 10 kDa (Luo et al., 1994, Wilson et al., 1990).  
Once secreted, the chemokine signals to cells expressing Chemokine Receptor 8 
(CCR8), the unique receptor for CCL1 (Roos et al., 1997; Tiffany et al., 1997), 
although interaction with at least one additional receptor may occur (Goya et 
al., 1998). 
The murine and human CCR8 proteins share 71% homology (Goya et al., 1998).  
CCR8 is a seven transmembrane domain G protein-coupled receptor and is highly 
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expressed in thymus, as well as spleen and colon (Zaballos et al., 1996, Zingoni 
et al., 1998; Goya et al., 1998).  mCCR8 is expressed on monocytes, CD4+ 
(helper) and CD8+ (cytotoxic) T lymphocytes (Tiffany et al., 1997; Zaballos et 
al., 1996; D’Ambrosio et al., 1998).  hCCR8 expression was shown to be specific 
to TH2 lymphocytes and not TH1 (Zingoni et al., 1998).  hCCR8 is also expressed 
on a subset of CD4+ memory T lymphocytes, enriched in TH2 and TREG cells, while 
only a small population of hCCR8+ TH1 and NK cells exist (Soler et al., 2006). 
2.5 Associated disease 
The chemokines are well known for their role in cell migration but they also play 
a role in disease.  The dysregulation of chemokines is often associated with 
inflammation and tissue injury.  mCCL1/hCCL1 has been implicated in asthma, 
atherosclerosis, diabetes and cancer and has both anti- and pro- apoptotic 
functions.  Studying the murine homologue in vitro provided an opportunity to 
characterise how HMGN3 regulates gene expression and identify potential 
epigenetic marks associated with mCCL1 expression. 
2.5.1 Asthma 
Higher levels of hCCL1 are present in the bronchoalveolar fluid (BALF) of atopic 
asthmatic patients than in non-asthmatic people (Montes-Vizuet et al., 2006).  
This correlates with an increase in lymphocytes and eosinophils (but not 
macrophages) and contributes to the inflammatory response.  BALF, a substance 
coating the bronchial airway epithelial lining, contained a six-fold higher level of 
hCCL1 in asthmatics compared with normals.  hCCL1 mRNA is constitutively 
expressed in bronchoalveolar cells in normal subjects but is much higher in 
asthmatics.  This study found increased levels of hCCL1 in BALF correlates with 
an increased number of lymphocytes.  In vitro assays show that bronchial 
epithelial cells release hCCL1 when stimulated by cytokines released by 
lymphocytes, such as IL-4 from TH2 cells.  The authors suggest hCCL1 released by 
the bronchoalveolar cells plays a role in lymphocyte recruitment in bronchial 
asthma. 
A similar study in mice looked at the role of mCCL1 in the development of 
allergic airway disease (Bishop and Lloyd, 2003).  After allergen challenge, 
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macrophages were identified as the primary source of mCCL1 in BALF and lung 
tissue.  Analysis shows allergen exposure causes an increase in both mCCL1 RNA 
and protein expression.  mCCL1 mediates the recruitment of eosinophils, but not 
TH2 lymphocytes.  The lack of an apparent TH2 recruitment in this study 
compared to that above may be due to the already increased number of TH2 
cells in BALF of mice.  Alternatively, the allergen presented to mice may 
activate alternative pathways from those in atopic asthmatics and thus, these 
pathways exert a different overall effect on the recruitment of TH2. 
2.5.2 Atherosclerosis 
The condition of atherosclerosis involves plaque formation, during which 
circulating monocytes associate with the vessel wall (Ross 1999).  An 
independent risk factor for atherosclerosis called Lipoprotein(a) [Lp(a)] (Seman 
et al., 1999) accumulates in blood vessel walls.  Lp(a) prevents the binding of 
plasminogen, the inactive precursor of plasmin that functions in clot lysing 
(Hajjar et al., 1989), and hence promotes plaque formation.  Lp(a) also 
promotes recruitment of monocytes to the vessel wall (Poon et al., 1997) and 
stimulates endothelial cells to produce hCCL1 (Haque et al., 2000), a potent 
monocyte chemoattractant.  This required de novo synthesis of hCCL1 and 
binding to hCCR8.  Immunohistochemical studies show hCCL1 present in human 
atherosclerotic plaques and extracellular matrix, which colocalised with Lp(a).  
This suggests Lp(a) may function to recruit monocytes and other hCCR8 
expressing cells, such as macrophages or lymphocytes, into the forming 
atherosclerotic plaque. 
A subsequent study found hCCL1 and Lp(a)-stimulated endothelial cell-
conditioned medium induced endothelial chemotaxis (Haque et al., 2001).  CCR8 
and hCCL1 are present on the luminal endothelium of the atherosclerotic plaque 
and in subendothelial tissue of the atherosclerotic plaque.  Endothelial 
chemotaxis was mediated through CCR8.  Based on previous results that 
suggested new vessel formation accompanied plaque growth (Moulton et al., 
1999), the authors suggest chemotaxis of endothelial cells by hCCL1, 
accompanied by other inflammatory cytokines, promotes new vessel growth. 
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2.5.3 Cancer 
Mouse myeloma cell lines J558 and P3X transfected with mCCL1 show impaired 
growth in both normal and immunodeficient mice (Laning et al., 1994).  After 21 
days of being tumour free, mice rechallenged 2-10 weeks later with 
nontransfected mCCL1 myeloma cells of the same myeloma cell line are 
resistant.  Mice transfected with the other cell line are not, indicating antigen 
specific tumour immunity. 
Injecting a mixture of mCCL1 transfected/nontransfected cells into mice 
produces retarded tumour growth, but an eventual tumour mass develops.  In 
contrast, injection of transfected or nontransfected cells into opposite flanks of 
the mouse causes growth inhibition only in mCCL1 transfected tumours. 
Further experiments show the mCCL1 anti-tumour effect is restricted to the 
early phase of tumour implantation, before a solid tumour develops, as mCCL1 
failed to impair growth at the site of an established tumour. 
Biopsies taken from mice injected with mCCL1 transfected myeloma cells 
contain high numbers of neutrophils, some monocytes and occasionally mast 
cells, 24 and 48 hours after implantation.  Tumour necrosis occurs, but not in 
control experiments, nor an influx of leukocytes.  Therefore, mCCL1 mediates 
inhibition of in vivo tumour growth by inducing an influx of immune cells that is 
likely mediated through interaction with the CCR8 receptor displayed by 
neutrophils, monocytes and mast cells. 
In contrast to the pro-apoptotic functions described for myeloma, mCCL1 has 
anti-apoptotic functions in thymomas and may mediate positive selection of 
thymocytes (Zingoni et al., 1998; Van Snick et al., 1996). 
An anti-apoptotic function for hCCL1 has been suggested for the progression of 
Adult T-cell leukaemia (ATL).  ATL-derived lymphocytes highly overexpress and 
secrete hCCL1 and express CCR8 (Ruckes et al., 2001).  Cell culture supernatant 
of ATL cells dramatically reduces the rate of dexamethasone-induced apoptosis, 
but this can be overcome with the addition of anti-hCCL1 antibodies.  
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Similarly, Fas induced apoptosis of ATL cells is enhanced when anti-hCCL1 
antibodies are added to the cell medium, while pertusis toxin, an inhibitor to 
the hCCL1 signalling, significantly increases apoptosis of ATL derived cells.  This 
suggests hCCL1 participates in an anti-apoptotic autocrine loop that may inhibit 
apoptosis in ATL cells and contribute to their growth. 
2.5.4 CCL1 concentration mediates cell response 
Aside from the role of mCCL1 in the recruitment of monocytes/macrophages and 
neutrophils, neutrophils and monocytes produce cell-damaging chemicals (Devi 
et al., 1995) which are associated with antitumour and antimicrobial action 
(Ding et al., 1988). 
Clearly, a coordinated series of events must ensue to control migration and 
release of harmful chemicals and enzymes to the appropriate target cells.  This 
seems to be controlled by the concentration of mCCL1 in the environment of the 
target cell.  At low concentrations (0.1nM), cell adhesion is induced and 
maintained (Devi et al., 1995).  As the concentration approaches 1nM, migration 
of cells including macrophages and neutrophils takes place.  As the 
concentration increases to 10nM and higher, reactive oxygen and nitrogen 
intermediates are released by macrophages and neutrophils.  This would explain 
the observed influx of monocytes and neutrophils observed in the study by 
Laning (Section 2.5.3), and account for the observed necrosis.  At the site of 
implanting mCCL1 expressing myeloma cells, the concentration of mCCL1 would 
be greatest and induce necrosis, while non-transfected mCCL1 cells implanted at 
a flanking site would not. 
2.5.5 Diabetes and other CCL1 associated disease  
mCCL1 also participates in the clearance of C. neoformans from the lungs and 
brains of mice, a fungal pathogen acquired through inhalation that can spread to 
the brain causing meningoencephalitis, which is fatal if untreated (Idnurm et al., 
2005).  mCCL1 attracts neutrophils to the site of infection which stimulate the 
production of mCCL3.  This in turn promotes recruitment of lymphocytes into 
the reaction site and to promote clearance.  A similar process of recruitment 
occurs in humans with the condition vernal keratoconjunctivitis (VKC), a disease 
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of the inner lining of the eyelids.  Monocytes and macrophages express hCCL1 
and recruit T lymphocytes which may contribute to the severity of VKC (El-Asrar 
et al., 2002). 
hCCL1 has also recently been characterised with a role in type 1 diabetes, 
involving macrophage recruitment and activation (Joseph Cantor and Kathryn 
Haskins, 2007). 
Thus, the chemokine hCCL1 may be an important therapeutic target for people 
suffering from various conditions.  Mouse and human studies of CCL1 will 
enhance our understanding of chemokine signalling in health and disease, and 
identify potential therapeutic targets to combat inflammation. 
 
Craig S Davis, 2008  41 
3 Aims 
Previously, HMGN3 was shown to reduce TNFα-induced mCCL1 gene expression, 
however, it was unknown how HMGN3 brought about this effect. 
The first aim was to confirm the previous studies finding that HMGN3 reduces 
TNFα-induced mCCL1 gene expression.  The second aim was to study the effect 
serum concentration had on the level of mCCL1 expression.  The third aim was 
to establish the optimal incubation time to induce mCCL1 mRNA expression 
following TNFα stimulation. 
To understand how HMGN3 regulates gene expression, ChIP assays were 
performed.  The level of HMGN3 bound at the mCCL1 gene in cells induced with, 
or without, TNFα was measured to establish whether HMGN3 has a direct role in 
regulating gene expression.  The level of acetylation at H3K14 was also 
investigated, as this mark is associated with transcribed genes.  ChIP assays were 
quantified using QRT-PCR analysis. 
Finally, to establish whether HMGN3 has an indirect role in regulating gene 
expression, NF-B and p38 luciferase assays were performed. 
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4 Materials and Methods 
4.1 Materials 
Agarose Multi Purpose Roche, Lewes, East Sussex, UK 
Axygen 0.2 and 0.5 ml thin wall clear flat cap PCR tubes Thistle Scientific, 
Glasgow, UK 
Axygen 1.5 ml and 1.7 ml MAXYMUM RECOVERY clear microtubes Thistle 
Scientific, Glasgow, UK 
Barrier Tips (10, 20, 200, 1000 µl) (RNase-DNase free, sterile) Neptune, USA 
Bromophenol Blue Fisher Scientific, Loughborough, UK 
DEPC-treated Water Invitrogen, Paisley, UK 
Doxycycline SIGMA, Poole, Dorset, UK 
Dual-Luciferase Reporter Assay System Promega, Southampton, UK 
EDTA (Ethylenediaminetetraacetic acid disodium salt dehydrate) SIGMA, Poole, 
Dorset, UK 
Ethidium Bromide Amresco, Ohio, USA 
Ethyl Alcohol 99.7% v/v min Hayman Limited, Witham, Essex, England 
FastStart SYBR Green Master (Rox) Roche, Lewes, East Sussex, UK 
Formaldehyde 37% Solution Amresco, Ohio, USA 
Glycerol BDH Laboratory Supplies, Poole, England 
Glycine Fisher Scientific, Loughborough, UK 
Glycogen (for molecular biology) Roche, Lewes, East Sussex, UK 
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Igepal CA-630 SIGMA, Poole, Dorset, UK 
IgG (1 mg/ml) from rabbit serum SIGMA, Poole, Dorset, UK 
Kb DNA Ladder Stratagene, Amsterdam, The Netherlands 
LightCycler 480 Multiwell Plate 96 Roche, Lewes, East Sussex, UK 
LightCycler 480 Sealing Foil Roche, Lewes, East Sussex, UK 
Lithium Chloride SIGMA, Poole, Dorset, UK 
MycoAlert Mycoplasma Detection Kit Cambrex/Lonza, Wokingham, Brerkshire, 
UK 
Optically Clear Heat Sealing Film Abgene, Epsom, Surrey, UK 
Phenol:Chloroform:Isoamyl Alcohol 25:24:1 (Saturated with 10 mM Tris, pH 8.0, 
1 mM EDTA) SIGMA, Poole, Dorset, UK 
Protease inhibitor cocktail tablets (Complete, EDTA-free) Roche, Lewes, East 
Sussex, UK 
Proteinase K from Tritirachium album SIGMA, Poole, Dorset, UK 
Protein G Agarose, Fast Flow (10 ml packed beads) 20 ml 50% slurry Upstate 
(Millipore), Wolverton Mill South, Milton Keynes, UK 
Random Hexamers (50 ng/µl) Invitrogen, Paisley, UK 
Recombinant Mouse TNFα (Catalogue Number 410-MT-010/CF) RnD Systems, 
Abingdon, Oxfordshire, UK 
Ribonuclease A from bovine pancreas SIGMA, Poole, Dorset, UK 
RNase-Free DNase Set Qiagen, Crawley, West Sussex, UK 
RNase H Invitrogen, Paisley, UK 
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RNaseOUT Recombinant Ribonuclease Inhibitor (40 U/µl) Invitrogen, Paisley, UK 
RNeasy Mini Kit Qiagen, Crawley, West Sussex, UK 
SafeViewTM Nucleic Acid Stain NBS Biologicals, Huntingdon, Cambridgeshire, UK 
Sodium Chloride BDH Laboratory Supplies, Poole, England 
SuperScriptTM III First-Strand Synthesis System for RT-PCR Invitrogen, Paisley, 
UK 
SuperScriptTM III Reverse Transcriptase Invitrogen, Paisley, UK 
SYBR® Green PCR Master Mix Applied Biosystems, Warrington, UK 
Tris Base Fisher Scientific, Loughborough, UK 
Triton X-100 Pharmacia Biotech, Uppsala, Sweden 
Water (DNase-RNase free, 0.1 µm filtered) SIGMA, Poole, Dorset, UK 
0.1 M DTT (Dithiothreitol) Invitrogen, Paisley, UK 
0.2 ml semi-skirted 96-well PCR plate (colour natural) Abgene, Epsom, Surrey, 
UK 
1 KB Plus DNA Ladder Invitrogen, Paisley, UK 
10 mM dNTP Mix (PCR Grade) Invitrogen, Paisley, UK 
10x First Strand Buffer Invitrogen, Paisley, UK 
25 mM MgCl2 Invitrogen, Paisley, UK 
100 bp DNA Ladder Invitrogen, Paisley, UK 
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4.1.1 Tissue culture plasticware and reagents 
Cell lifter Corning, NY, USA 
Centrifuge Tube (15 ml and 50 ml) Corning, NY, USA 
DMEM + GlutaMAX-1 (1X) 32430 Invitrogen, Paisley, UK 
DPBS - Dulbecco’s Phosphate Buffered Saline without Ca and Mg (10x) 
Lonza/Cambrex, Wokingham, Brerkshire, UK 
Hygromycin B in PBS 50 mg/ml Invitrogen, Carlsbad, CA, USA 
LipofectaminTM 2000 Transfection Reagent Invitrogen, Carlsbad, CA, USA 
Multidish 6 wells Nunc, Roskilde, Denmark 
Pipette (1 ml, 5 ml, 10 ml, 25 ml, 50 ml) Corning, NY, USA 
Tet-free USDA System Approved Foetal Bovine Serum Clontech, Saint-Germain-
en-Laye, France 
TC dish 100x20 SI, TC Dish 140x20 Nunc, Roskilde, Denmark 
Trypan Blue Stain 0.4%, Opti-MEM (1X) Invitrogen, Paisley, UK 
Zeocin Invitrogen, Carlsbad, CA, USA 
0.25% Trypsin-EDTA (1x) Invitrogen, Paisley, UK 
5 ml Polystyrene Round-Bottomed Tube (FACS tubes) BD Biosciences, 
Erembodegem, Belgium 
50 ml Reagent Reservoir Corning, NY, USA 
96 Well Assay Plate, (White Plate, Clear Bottom with Lid, Tissue Culture 
Treated, Polystyrene, Sterile) Corning, NY, USA 
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4.1.2 Antibodies 
Anti-acetyl-Histone H3 (Lys14) (Rabbit, Polyclonal) Catalogue Number: 07-353 
Upstate, UK 
Mouse HMGN3 Ab: mN3Ab – EPO 62146 
4.1.3 Primers 
CCL1 genomic (QRT-PCR) primers (Table 1) Eurogentec, Southampton, 
Hampshire, UK 
Globin and Glyt1 genomic primers (Table 1), cDNA primers (Table 2) MWG 
(Eurofins), Worple Park, London 
4.1.4 Lab equipment 
BIOHIT e120 automatic pipette Alpha laboratories, Eastleigh, Hampshire, UK 
Thermocycler T3000 Biometra, Germany, Thistle Scientific 
Thermo-sealer ABGene (Advanced Biotechnologies Ltd) Surrey, UK 
LightCycler480 Roche, Mannheim, Germany 
Microscope Olympus CK2 Olympus, Watford, England 
Luminoskan Ascent Thermo Fisher Scientific, Ulm, Germany 
Nanodrop ND-1000 Spectrophotometer Thermo Fisher Scientific, Ulm, Germany 
Phosphoimager FLA-5000 Fujifilm, CT, USA 
Plate Reader Dynatech MR7000 (Mycoplasma assays) Dynatech Laboratories 
Incorporation, Guernsey, UK 
Sonicator 3000 Misonix Incorporated, NY, USA 
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Stratagene Mx3000P Stratagene, Amsterdam, The Netherlands 
4.2 Buffers 
4.2.1 General buffers 
Phosphate buffered saline (PBS) (10x) 
Isotonic buffer for washing cells 
4.2.2 ChIP buffers 
5% Formaldehyde Solution 
5% CH2O, 50 mM Tris pH 8.0, 0.1 M NaCl, 1 mM EDTA 
1M Glycine solution 
1 M Glycine 
Cell lysis buffer 
10 mM Tris pH 8.0, 10 mM NaCl, 0.2% Igepal CA-630.  1 protease inhibitor 
cocktail added per 10 ml prior to use. 
Nuclei lysis buffer 
50 mM Tris pH 8.0, 10 mM EDTA, 0.5% SDS 
IP dilution buffer 
12.5 mM Tris pH 8.0, 0.19 M NaCl, 0.01% SDS, 1.2% Triton X-100 
IP wash I 
20 mM Tris pH 8.0, 0.15 M NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton X-100 
High salt buffer 
20 mM Tris pH 8.0, 0.5 M NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton X-100 
IP wash II 
10 mM Tris pH 8.0, 0.25 M LiCl, 1 mM EDTA, 1% Igepal CA-630, 0.5% Sodium 
Deoxycholate 
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Tris-EDTA (TE) buffer 
10 mM Tris pH 8.0, 1 mM EDTA 
Elution buffer 
1% SDS, 0.1 M NaHCO3 
4.2.3 Molecular biology solutions 
DNA/RNA loading buffer 
0.25% (w/v) bromophenol blue, 10% (v/v) 1x PBS, 50% (v/v) glycerol in DNase-
RNase-free H20 
4.3 Cell culture and treatments 
4.3.1 Cell preparation 
Cell culture was performed in a Class II cabinet using sterile equipment and 
reagents.  Cells previously aliquoted into cryo-tubes and stored in liquid nitrogen 
were thawed rapidly by placing in a 37oC water bath.  Cells were immediately 
added to 9 ml fresh media, centrifuged at 155 x g for 4 minutes and supernatant 
removed to remove dimethylsulphoxide (DMSO).  Cells were then resuspended in 
fresh media. 
4.3.2 Mouse embryonic fibroblast T23 cells 
Previously, SV-40-immortalised Hmgn1-/- mouse embryonic fibroblast (MEF) cells 
were stably transfected with pTet-On, pSV-Zeo, pTK-Hyg, and the HMGN3 gene 
bearing tetracycline-responsive promoters.  pTet-On expresses a tetracycline-
controlled transactivator consisting of a bacterial Tet Repressor fused to three 
repeats of a minimal VP16 transcription activation domain.  In the presence of 
Doxycycline (Dox), the transactivator activates transcription from the Tet 
promoter inducing HMGN3 expression.  These cells (T23) are adherent and grow 
in monolayer. 
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4.3.3 Cell incubation conditions 
T23 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% foetal bovine serum (FBS), 250 µl Zeocin and 800 µl 
Hygromycin.  Cells were maintained in a humidified incubator of 95% air, 5% CO2 
at 34oC.  2 µg/ml Dox was added to the appropriate cells to induce HMGN3.  
Experiments where TNFα (0.05 µg/µl) was added, cells were incubated as 
described, however the 24 hours preceding TNFα induction the cell media was 
replaced with DMEM supplemented with only 0.1% FBS, no antibiotics, only Dox 
to the appropriate cells.  At the time of adding TNFα, the media was replaced 
with the DMEM containing 0.1% FBS*, Zeocin and Hygromycin. 
*The effect of using 0.1% and 10% FBS was investigated and shown in Figure 5. 
4.3.4 Subculturing of cells 
Upon reaching 80-95% confluency, cells were sub-cultured.  Media was aspirated 
and cells washed with 10-20 ml Phosphate Buffered Saline (1x) for 2-3 minutes.  
After removing PBS, 2-3.5 ml of 0.25% Trypsin-EDTA (1x) solution was added 
until cells detached from dish.  Then, 4-7 ml of fresh medium was immediately 
added to neutralise the Trypsin before sub-culturing cells to a new dish 
containing fresh media.  The MycoAlert Mycoplasma Detection Kit was 
occasionally used to test for contamination. 
4.4 Reverse transcriptase polymerase chain reaction 
4.4.1 RNA extraction 
Total RNA was extracted from 5 x 105 cells growing in six well plates using an 
RNeasy Mini Kit (Qiagen) following the manufacturers animal cell protocol.  Cells 
were washed with PBS before commencing the protocol.  Lysate was flash frozen 
on dry ice before storing at -80oC.  Thawing of lysate from -80oC ensured adequate 
disruption and homogenisation of samples to produce sufficient RNA yields.  The 
optional DNase digestion step was performed as per manufacturer’s protocol.  
Samples were stored at -20oC or used immediately to synthesise first strand cDNA. 
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4.4.2 RNA gel electrophoresis 
Total RNA samples were resolved by agarose gel electrophoresis to determine 
RNA integrity.  Agarose gels (1-1.5%) were made by boiling agarose powder in 50 
ml 1x TBE buffer in a microwave oven.  Then, 1 µl of ethidium bromide or 0.3 µl 
SafeViewTM nucleic acid stain was added prior to casting the gel.  The 
concentration of each RNA sample was determined using Nanodrop ND-1000, 
before 300 ng of RNA mixed with loading buffer was electrophoresed at 90-100 V 
for about 1 hour.  A 1KB Plus DNA Ladder was loaded to clarify the size of 
ribosomal RNA bands.  Images were taken using a phosphoimager.  Clear and 
distinct 28S and 18S ribosomal RNA bands were visible on the gel image, 
indicating intact RNA samples.  RNA was then reverse transcribed to produce 
cDNA. 
4.4.3 First strand cDNA synthesis 
cDNA was synthesised from total RNA using the SuperScriptTM III First-Strand 
Synthesis System for RT-PCR (Invitrogen).  300 ng of total RNA was added to a 
0.2 ml thin walled PCR tube, together with 1 µl random hexamers (50 ng/µl), 10 
mM dNTP mix and made up to 5 µl with DEPC-treated water.  Samples were 
incubated at 65oC for 5 minutes then placed on ice for at least 1 minute.  cDNA 
Synthesis Mix was prepared using half manufacturers recommended volumes.  1 
µl 10x RT (Reverse Transcriptase) buffer, 2 µl 25 mM MgCl2, 1 µl 0.1 M DTT 
(Dithiothreitol), 0.5 µl RNaseOUT (40 U/µl) and 0.5 µl SuperScriptTM III RT (200 
U/µl) were combined and 5 µl added to each RNA/primer mixture.  All samples 
were mixed gently before incubating for 10 minutes at 25oC, followed by 50 
minutes at 50oC, 5 minutes at 85oC then 15 minutes at 4oC.  RNase H (0.5 µl) was 
added to each sample and incubated for 20 minutes at 37oC.  The resulting 10.5 
µl cDNA samples were stored at -20oC. 
4.4.4 QRT-PCR of cDNA 
Quantitative Real Time-PCR (QRT-PCR) is a suitable method for comparing the 
level of gene expression in induced cells to those uninduced (HNGN3 
induced/uninduced, CCL1 induced/uninduced).  QRT-PCR reactions were 
performed using 0.21 µl of cDNA diluted in 4.79 µl of DNase-RNase free water 
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per 25 µl reaction.  12.5 µl of SYBR® Green PCR Master Mix (Applied Biosystems) 
(containing dNTP’s, buffer, polymerase, SYBR green, Rox dye) together with 50 
or 900 nM forward and reverse primers were added, with the final volume made 
up to 25 µl with DNase-RNase free water.  The primers used for QRT-PCR are 
listed in Table 2.  GAPDH served as an internal control to normalise any 
differences in total cDNA input between samples that may arise due to 
efficiency of RNA purification, reverse transcription or from pipetting error.  
Samples were loaded to a 0.2 ml semi-skirted 96-well PCR plate (colour natural) 
using an automatic dispensing pipette, sealed, then centrifuged at 125 x g for 1 
minute to collect samples before being loaded into a Stratagene MX3000P PCR 
machine.  QRT-PCR reactions were carried out using the following conditions: 10 
minutes at 95oC, followed by 45 cycles consisting of 15 seconds at 95oC and 1 
minute at 60oC.  Data was analysed using the Stratagene MX3000P v3.20 
software.  The reference dye Rox was used to normalise the minor differences 
present between samples well, such as differences in the volume of QRT-PCR 
reaction or transparency of Sealing Film.  The ΔΔCt method of analysis was 
carried out in excel to analyse the results. 
4.5 Chromatin immunoprecipitation techniques 
4.5.1 Fixation conditions 
The following procedure was used to carry out ChIP. 
T23 MEF cells were incubated as described previously in Section 4.3.3.  Cells 
were grown on five 140 mm dishes to 80-90% confluency, with an additional 
plate reserved to count cells using a haemocytometer and to extract total RNA 
in some cases.  Typically, 1 x 107 cells per 140 mm dish were used for each ChIP 
condition.  Cells were placed on a rocker and fixed with 5% formaldehyde 
solution (10% of media volume (v/v)), then left for 5 minutes before fixations 
were quenched by addition of 2.25 ml 1 M glycine.  Media was aspirated and 
cells washed in 20 ml ice-cold 1x PBS for 2 minutes.  Cells were harvested by 
adding 8 ml ice cold 1x PBS and collected by scraping, then transferred to a 50 
ml falcon tube, centrifuged at 220 x g for 5 minutes and supernatant removed.  
Cells were swelled/lysed using 5 pellet volumes (3.3 ml) of ice cold Cell Lysis 
Buffer, left on ice 10 minutes, centrifuged 5 minutes at 220 x g to pellet nuclei 
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and supernatant removed.  Pelleted nuclei were lysed with ice cold Nuclei Lysis 
Buffer (2 ml), with the nuclei pellet disrupted by pipette action.  Samples were 
either left on ice 10 minutes or frozen and stored at -20oC. 
4.5.2 Sonication conditions 
Chromatin samples were transferred from a falcon tube to a 5 ml FACS tube for 
sonication by a Misonix Sonicator 3000.  The microtip was placed approximately 
1/3 of the way into the sample.  A beaker containing ice was placed around the 
tube.  The following settings were applied for sonication: 2 minutes on time: 10 
seconds on, 30 seconds off, 6 watts, output three; i.e. each sample to be 
sonicated takes 8 minutes. 
4.5.3 Preparation of DNA fragments for electrophoresis 
A 100 µl aliquot of chromatin was combined in a tube with 6 µl 5 M NaCl2, 1 µl 1 
mg/ml RNase and incubated at 65oC for 4 hours.  Then, 3 µl 24.1 mg/ml 
proteinase K was added and incubated overnight at 45oC.  The following day 100 
µl Phenol:Chloroform was added, mixed, centrifuged at 14 500 x g for 5 minutes 
then the top layer containing DNA transferred to a new tube.  This step was 
repeated to reduce the protein content.  Having transferred the DNA to a new 
tube, 2 volumes 100% ethanol and 1/10 volume 3 M Sodium Acetate were added 
and the sample incubated for 15 minutes at -20oC, then centrifuged at 18 000 x g 
for 15 minutes at 4oC.  Supernatant was removed, 1 ml 70% ethanol added, 
mixed and centrifuged for 10 minutes at 18 000 x g.  Supernatant was removed 
and sample left for about 15 minutes at room temperature (RT) to air dry.  
Sample was resuspended in 100 µl distilled water. 
4.5.4 DNA gel electrophoresis 
DNA fragments were resolved by agarose gel electrophoresis to determine the 
size range of chromatin fragments produced after sonication.  A 1.5% agarose gel 
was made by boiling agarose powder in 50 ml 1x TBE buffer in a microwave 
oven.  Then 1 µl of ethidium bromide or 0.3 µl SafeViewTM stain was added prior 
to casting the gel.  A DNA volume of 10 µl, mixed with 1.5 µl loading buffer and 
2.5 µl DNase-RNase-free water were subjected to electrophoresis at 90-100 V for 
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about 1 hour.  A 100 bp (1.5 µl) and 1kB (2.5 µl) marker mixed with 1.5 µl 
loading buffer and made up to 15 µl with DNase-RNase-free water were also 
added.  Images were taken using a phosphoimager.  Fragments in the range of 
~400-1200 base pairs of DNA were ideally sought after and were visible as a 
smear on the gel. 
4.5.5 Pre-clearing chromatin 
After confirmation of the range of sonicated chromatin fragments, sonicated 
samples were pre-cleared.  The samples were diluted in a 15 ml falcon tube with 
IP Dilution Buffer to a final volume of 4.5 ml.  To this, 50 µl (1 mg/ml) IgG (from 
rabbit serum) were added to each sample and left for 1 hour at 4oC with 
rotation.  Meanwhile, 200 µl 50% Protein G Agarose beads were centrifuged at 4 
150 x g for 2 minutes and supernatant removed.  These beads were washed 
three times with 100 µl IP Dilution Buffer, centrifuging at 4 150 x g for 2 
minutes.  Protein G Agarose beads were resuspended using 500 µl of the 
chromatin/IgG solution and then transferred back to the falcon tube.  Samples 
were incubated at 4oC overnight on rotation at 15 rpm.  Next day, chromatin was 
centrifuged at 1 690 x g for 2 minutes at 4oC, then supernatant transferred to a 
new 15 ml falcon tube, centrifuged at 1 690 x g for 2 minutes at 4oC to remove 
any non-specific chromatin bound IgG beads. 
4.5.6 Immunoprecipitation of chromatin 
Pre-cleared chromatin was aliquoted for each immunoprecipitation condition, 
900 µl per condition.  The following conditions were used: No antibody, IgG, 
HMGN3 Antibody, Anti-acetyl-Histone H3 (Lys14) Antibody (Upstate).  A no 
chromatin control was included in which 900 µl IP Dilution Buffer were used in 
place of chromatin, while a 180 µl chromatin sample controlled for the starting 
material was delegated input.  The desired quantity of antibody was added to 
the appropriate 900 µl chromatin and left at 4oC for 2 hours on rotation (4.8 µg 
IgG, 4.8 µl H3K14ac, 12 µg mN3Ab).  The input sample was left at 4oC on rotation 
until the reversal of protein-DNA crosslinks was carried out.  Protein-DNA 
complexes were precipitated with 72 µl 50% Protein G Agarose beads which had 
been prepared by centrifuging at 5 150 x g for 2 minutes at 4oC and supernatant 
removed.  After 2 hours, the chromatin/antibody solution was centrifuged at 18 
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000 x g for 5 minutes at 4oC before transferring supernatant to tube containing 
the Protein G Agarose beads, mixed and left at 4oC for 2 hours on rotation at 20 
rpm.  The beads/chromatin were then centrifuged at 5 150 x g for 2 minutes at 
4oC.  Having removed the supernatant a series of washes followed.  First, 500 µl 
IP Wash I was added, vortexed briefly, centrifuged 2 minutes at 5 150 x g at 4oC 
then supernatant removed.  Another 500 µl IP Wash I added, mixed then 
transferred to a new 15ml falcon tube, centrifuged at 5 150 x g for 2 minutes, 
4oC and supernatant removed.  Beads were next washed with 500 µl High Salt 
Buffer, centrifuged at 5 150 x g, 2 min, 4oC, supernatant removed then washed 
with 500 µl IP Wash II, centrifuged as previous and supernatant removed.  A 
subsequent two washes of the beads with 500 µl TE Buffer, centrifuged as 
before, then removal of supernatant completed the washes.  To elute 
chromatin, 150 µl Elution Buffer was added to the beads, vortexed briefly, 
centrifuged 2 minutes at 5 150 x g at room temperature.  Supernatant was 
collected before a second elution with a fresh 150 µl Elution Buffer was 
conducted in the same way, with the two elutes being combined.  Protein-DNA 
crosslinks were removed by adding 20 µl 5 M NaCl (10.8 µl for input), along with 
1µl RNase (1 mg/ml) (to degrade RNA and aid purification of DNA), and left at 
65oC for 4 hours.  Then 3 µl (20 mg/ml) proteinase K was added and left at 45oC 
overnight. 
4.5.7 Recovery of DNA 
DNA was recovered from samples using Phenol:Chloroform.  TE (120 µl) was 
added to input sample, before 300 µl Phenol:Chloroform was added to all 
samples, vortexed, centrifuged at 18 000 x g for 5 minutes and top layer 
transferred to a new tube.  To each sample was added 30 µl 3 M sodium acetate 
(pH 5.2) and 0.5 µl glycogen (10 mg/ml), mixed then 750 µl 100% ethanol added, 
mixed and subsequently incubated at -20oC for at least 30 minutes.  Samples 
were centrifuged at 18 000 x g for 15 minutes at 4oC, supernatant removed then 
800 µl 70% ethanol added, mixed by inversion and centrifuged at 18 000 x g for 5 
minutes.  Supernatant was removed and samples left to air dry at room 
temperature.  DNA was resuspended in 200 µl RNase-DNase-free water at 50oC 
for 5 minutes.  DNA was then used immediately for QRT-PCR or stored at -20oC. 
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4.5.8 QRT-PCR of DNA 
Immunoprecipitated DNA was quantified using QRT-PCR.  QRT-PCR reactions 
were carried out in a total volume of 25 µl containing 5 µl of 
immunoprecipitated DNA, 12.5 µl FastStart SYBR Green Master Mix (Roche), 300 
or 900 nM forward and reverse primers and prepared to a final volume of 25 µl 
with DNase-RNase free water.  The primers used for QRT-PCR are listed in Table 
1.  Samples were loaded to a 0.2 ml semi-skirted 96-well PCR plate (colour 
natural) using an automatic dispensing pipette, sealed then centrifuged at 125 x 
g for 1 minute before being loaded into a Stratagene MX3000P PCR machine.  
The PCR reactions were carried out using the following conditions: an activation 
step of 1 cycle 10 minutes 95oC, an amplification phase consisting of 40 cycles of 
denaturation 10 minutes 95oC, annealing 1 minute 55oC, extension 30 seconds 
72oC, then 1 cycle consisting of 1 minute 95oC, 30 seconds 55oC, 30 seconds 95oC 
to generate a dissociation curve.  Data was analysed using the Stratagene 
MX3000P v3.20 Build 340, Schema 74 software.  The reference dye Rox was used 
to normalise the minor differences present between samples well, such as 
differences in the volume of QRT-PCR reaction or transparency of Sealing Film.  
Results were calculated as fold enrichment of immunoprecipitated DNA over 
input, rather than the ΔΔCt method, as the reference gene, β-Globin, was found 
to bind HMGN3. 
4.6 Dual-luciferase reporter assay system 
This assay requires the simultaneous expression and measurement of Photinus 
pyralis (firefly) and Renilla reniformis (Renilla) activity from the one sample.  
The firefly reporter is correlated with the effect TNFα has on Dox-induced and 
uninduced cells, while Renilla normalises for variability between samples that 
may arise due to differences in cell viability, transfection efficiency or 
differences in pipetting volumes. 
4.6.1 Transfection 
T23 cells were plated onto a white 96-well, clear bottomed plate at a density of 
2.22 x 104 cells per well and grown in 50 µl of medium overnight as described in 
Section 4.3.3.  Cells were transfected the following day with a combination of 
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the plasmids listed in Table 3.  For each reaction, 1–40 ng of the appropriate 
plasmids and 25 µl of Opti-MEM (1x) were added to a tube, mixed and left at RT 
for 5 minutes.  Meanwhile, for each reaction 0.26 µl of LipofectaminTM 2000 
Transfection Reagent (Invitrogen) and 25 µl Opti-MEM (1x) were added to a 15 ml 
falcon tube, mixed and left at RT for 5 minutes.  After 5 minutes, the 
appropriate volume of transfection mix from the falcon tube was added to the 
tubes containing plasmids, mixed then left at RT for 20 minutes.  During this 
time, cells were washed with PBS, before replacing media with 50 µl DMEM + 
GlutaMAX-1 (1x) containing no antibiotics.  Dox (0.1 µl of 2 µg/ml) was added to 
the appropriate wells.  Finally, 50 µl of the transfection mix containing plasmids 
was added to the correct wells and the cells returned to the incubator for 24 
hours.  After the incubation period, cells were washed with PBS before 50 µl 
DMEM + GlutaMAX-1 (1x) supplemented with 0.1% serum medium was added.  
Another 50 µl of 0.1% serum medium containing 2x concentrate of 0.05 µg/µl 
TNFα and or 2x concentrate of 2 µg/ml Dox were added to the appropriate 
wells, while uninduced cells received a further 50 µl of 0.1% serum medium only.  
Cells were returned to the incubator for 24 hours to allow protein synthesis of 
luciferase. 
4.6.2 Dual luciferase assay 
The luciferase assay was performed using the Dual-Luciferase® Reporter Assay 
System (Promega).  Having prepared the kit reagents as per manufacturers 
guidelines and primed the luminometer injectors, cells were removed from the 
incubator and washed with 100 µl PBS before 40 µl PLB (1x) was added to the 
cells and left at RT on a rocker for 15 minutes.  The 96-well clear-bottomed 
plate was read using a luminometer.  Raw data was exported to MS excel, 
normalised and analysed. 

























Glyt 14727F GGTACTCATGGAACATGGTGCTG 
Glyt 14727R CCAGATGTGGTTGGATACCCA 
Glyt 18231F GTGCCCAGGAATTGTACTAATCAATA 
Glyt 18231R CCACACCCTCTCTCCCCATAG 
Table 1  Genomic QRT-PCR primers 













mN3-212R  CCAGCTTCCTGCTTTTCTTCC 
tca3-163F  CTATTGGAGACCGTAAGCATGCT 
tca3-113R  CGTGTGGATACAGGATGTTGACA 
Table 2  cDNA QRT-PCR primers 









pNF-B-Luc NF-B Reporter 
pFC-MEKK Positive NF-B Control 
pCIS-CK Negative NF-B Control 
  
pFR-Luc Fusion Reporter 
pFA2-CHOP Fusion Trans-Activator 
pFC-dbd Negative Fusion Control 
pFC-MEK3 Positive Fusion Control 
  
pRL-TK Renilla Reporter 
Table 3  Plasmids 
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5 Results 
5.1 mCCL1 expression 
The aim of the first experiment was to confirm the previous finding that HMGN3 
reduces the level of TNFα-induced mCCL1 expression.  This work was done in 
T23 cells, which are Tet-On MEFs that induce HMGN3 expression upon exposure 
to Dox (Section 4.3.2).  The cells were grown in the presence or absence of Dox 
in 10% serum medium and then arrested by reducing the serum concentration to 
0.1%.  Growth arrest served to ensure gene expression be at a minimal level 
prior to TNFα induction.  After 16-24 hours, 0.05 µg/µl TNFα was added together 
with fresh 10% serum medium and left to incubate for 4-6 hours, before 
harvesting for RNA. 
The effect of adding fresh 10% serum medium on mCCL1 expression was 
unknown.  In order to determine whether the fresh serum was important for the 
effect of HMGN3, this experiment was repeated as before, but with an 
additional experiment where fresh 0.1% serum medium was added at the time of 
adding TNFα.  RNA was extracted 4 hours later and analysed by quantitative RT-
PCR (QRT-PCR). 
The data shows induction of HMGN3 with Dox is not affected by the serum 
concentration in either TNFα-induced or uninduced cells, with a ~28 and ~24-
fold increase in expression, respectively (Figure 5A).  However, HMGN3 
expression is slightly lower in cells induced with TNFα. 
The data shows that 10% serum medium enhanced the level of TNFα-induced 
mCCL1 expression in HMGN3 induced cells from 17 to 48-fold and in HMGN3 
uninduced cells from 33 to 64-fold (Figure 5B).  This data also shows HMGN3 
reduces the level of TNFα-induced mCCL1 expression by around 50% in low serum 
conditions, from 33 to 17-fold, and is reduced in 10% serum medium from 64 to 
48-fold (Figure 5B), thus, confirming the previous finding. 
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Figure 5  HMGN3 reduces the level of TNFα-induced mCCL1 expression. 
Whole cell RNA was extracted from T23 MEFs, and HMGN3 and mCCL1 expression analysed by 
QRT-PCR.  Sample data was normalised to GAPDH and to the corresponding gene expression 
in uninduced T23 MEFs.  Primer sequences shown in Table 2.  Cells were treated with or 
without 0.05 µg/µl TNFα, 2 µg/ml Dox, as described in Materials and Methods Section 4.3.3.  
TNFα and Dox was mixed with either fresh 0.1% (-) or 10% (+) serum medium prior to being 
added to cells, then left to incubate for 4 hours.  (A)  HMGN3 RNA expression data.  (B)  
mCCL1 RNA expression data.  Data presented were obtained from three experimental 
replicates, with triplicate QRT-PCR reactions for each.  Data points represent means±SEM. 
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5.2 TNFα-induced mCCL1 expression 
Although previous results had shown mCCL1 mRNA expression increased with 4-6 
hours of TNFα incubation, the optimal incubation time was unknown.  To 
determine this, RNA was extracted every 30 minutes from TNFα-induced T23 
cells, over a period of 6 hours.  QRT-PCR analysis of cDNA synthesised from the 
extracted RNA revealed mCCL1 expression was greatest after 2 hours incubation 
with TNFα (Figure 6).  Elevated levels of mCCL1 expression were detectable 
within 30 minutes of adding TNFα, peaking at 2 hours with approximately 70-fold 
increase over uninduced cells.  mCCL1 mRNA expression remained elevated for 
the duration of the 6 hour period, being around 40-fold higher at 4 hours and 13-
fold at 6 hours. 
From the data obtained in Sections 5.1 and 5.2, all future experiments required 
T23 cells to be arrested in 0.1% serum medium, typically for 24 hours, then 
receive fresh 0.1% serum medium with or without 0.05 µg/µl TNFα, with or 
without 2 µg/ml Dox, before being harvested 2 hours after TNFα induction. 




























Figure 6  Time course of TNFα-induced mCCL1 expression. 
Whole cell RNA was extracted from MEFs at the specified time points and mCCL1 expression 
analysed by QRT-PCR.  Gene expression values were normalised to GAPDH and to mCCL1 
expression of cells at time point zero hours.  Primer sequences shown in Table 2.  Cells were 
treated as described in Materials and Methods Section 4.3.3 with 0.05 µg/µl TNFα, 10% serum 
medium, but without inducing for HMGN3 (no Dox added).  Data presented were obtained 
from three experimental replicates, with triplicate or duplicate QRT-PCR reactions for each.  
Data points represent means±SEM. 
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5.3 ChIP for HMGN3 at mCCL1 gene 
The HMGN family are nucleosome-binding proteins.  Previous studies identified 
HMGN3 target genes, including Glyt1a (West et al., 2004b).  HMGN3 up-regulates 
Glyt1a expression (in Hepa-1 cells) and is recruited to the Glyt1a gene in cells. 
ChIP assays were performed to show whether HMGN3 binds directly to the 
mCCL1 gene in T23 MEFs.  Cells grown in the presence or absence of Dox were 
incubated with or without 0.05 μg/μl TNFα for 2 hours and then fixed with 
formaldehyde as described in Material and Methods Section 4.5.  Chromatin 
fragments were prepared by sonication, then immunoprecipitation for HMGN3 or 
H3K14ac carried out.  Chromatin fragment lengths in the range of 400-1200bp 
were sought and detected from agarose gel electrophoresis.  Both the sonication 
conditions and antibody concentration for immunoprecipitation were optimised 
(data not shown).  The level of HMGN3 associated with the mCCL1 gene was 
assayed using QRT-PCR primer sets corresponding to the mCCL1 gene and the 
flanking genomic regions.  Exact primer sequence locations are illustrated in 
detail in Appendix I.  Primer concentrations were optimised and dilution series 
carried out to show linearity (data not shown).  The ChIP results presented 
reflect the level of HMGN3 bound at the region encompassed by the primer set 
at any given time due to the constant association and disassociation of HMGN 
proteins on chromatin. 
5.3.1 HMGN3 binds mCCL1 chromatin 
Cells grown in the absence of both Dox and TNFα indicate HMGN3 binds to the 
mCCL1 gene, with enrichment ranging from 2.5 to 10-fold (Figure 7A, blue line, 
open circles; see also Figure 7E), while cells grown in the presence of Dox have 
much higher enrichment levels, ranging from 41 to 91-fold (Figure 7A, red line, 
open squares; Figure 7C). 
TNFα treatment of Dox cells reduced HMGN3 binding to a fairly constant level of 
50-fold enrichment across the locus (Figure 7A, red line, closed squares; Figure 
7D).  Similarly, TNFα treatment of no Dox cells reduced HMGN3 binding from 
2.5-10 fold to approximately 3-fold across the locus (Figure 7A, blue line, closed 
circles; Figure 7F).  IgG controls are also shown (Figure 7, panels C-G). 
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Figure 7  ChIP assays for HMGN3 binding and H3K14ac across the mCCL1 gene in T23 MEFs.   
Panels A and B collate HMGN3 and H3K14 data, respectively, from panels C-F for ease of 
interpretation.  Panels A and B show the mCCL1 gene and exons in black from 5’ to 3’, with 
numbering relative to the transcription start site (+1).  Regulatory sites NRE-1a (-1999), NRE-
2b (-1362), NF-B (-194) and TATA box (-29) are indicated.  mCCL1 primer sequences 
indicated by A, H, I, K, O, and T can be found in Table 1 and Appendix I.  Location of primers 
in panels C-F are shown to scale in panel G.  Cells were incubated with 0.05 μg/μl TNFα for 2 
hours and then fixed with formaldehyde as described in Material and Methods Section 4.5.  
Enrichment levels are relative to input DNA.  Data presented were obtained from triplicate 
QRT-PCR assays.  Data points represent means±SD. 
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Figure 7  (continued) 
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5.4 ChIP for H3K14ac at mCCL1 gene 
Having shown HMGN3 binds at the mCCL1 gene, ChIP assays were performed for 
the histone modification H3K14ac.  This epigenetic mark is characteristic of 
active transcription start sites and promoter regions (Poholok et al., 2005; Roh 
et al., 2005).  In addition, evidence suggests upon TNFα stimulation, IKKα 
mediates acetylation of H3K14 and phosphorylation of H3S10, stimulating 
transcription. 
5.4.1 H3K14ac across mCCL1 gene 
Induction of HMGN3 with Dox causes an increase in H3K14ac across the mCCL1 
gene, from 4-12 fold to 20-80 fold enrichment (Figure 7B, compare blue line, 
open circles with the red line, open squares; Figure 7E and 7C).  Noticeably, 
H3K14ac peaks at -4973 and -690bp from the TSS.  Interestingly, TNFα treatment 
of Dox cells reduced the level of H3K14 acetylation by around 50% (Figure 7B, 
compare red line, open squares to red line, closed squares).  In particular, a 
marked reduction in acetylation occurred at the previous peaks at -4973 and -
690bp, almost abolishing these acetyl peaks.  Similarly, following TNFα induction 
of no Dox cells, H3K14ac levels decreased from 4-12 fold to 1-3 fold (Figure 7B, 
compare blue line open circles with blue line, closed circles; Figure 7E and 7F).  
Ideally, for each condition (ie. with or without Dox, with or without TNFα) 
parallel experiments with Histone H3 core antibodies should be carried out to 
normalise for potential differences in nucleosome density between induced and 
uninduced cells, and to account for any differences in antibody affinity. 
5.5 Summary - H3K14ac tracks with HMGN3 
These data show HMGN3 levels partially track with H3K14ac levels.  Dox-induced 
cells have high levels of H3K14ac at the mCCL1 gene, in particular at peaks -
4973 and -690bp which correlate with HMGN3 peaks.  Upon TNFα stimulation, 
the levels of H3K14ac at the mCCL1 gene fall, and this fall correlates with 
reduced HMGN3 binding.  This suggests HMGN3 recruits H3K14ac activity, similar 
to that of HMGN1 which was found to elevate H3K14ac levels by enhancing HAT 
activity (Lim et al, 2005). 
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To investigate whether HMGN3 modulates acetylation of H3K14 at other gene 
loci, ChIP was performed at two locations on the Glyt1 gene.  Importantly, Glyt1 
is not transcribed in T23 cells.  Cells grown in the absence of Dox indicate 
HMGN3 binds to the Glyt1 gene (Figure 8).  In the presence of Dox, enrichment 
of HMGN3 at the Glyt1 gene is increased from 22 to 57-fold, however, H3K14ac 
levels remain steady at around 20-fold (Figure 8), showing HMGN3-enhanced 
acetylation is not universal. 
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Figure 8  ChIP assays for HMGN3 or H3K14ac enrichment at the Glyt1 gene in T23 MEFs. 
Cells were grown then fixed with formaldehyde as described in Material and Methods Section 
4.5.  Enrichment levels are relative to input DNA and were determined by QRT-PCR.  Glyt1 
primer sequences shown in Table 1.  The positions of the two Glyt1 primer sets are shown 
beneath the graph as vertical arrows.  The two Glyt1 promoters (1a and 1b/c) and exons are 
shown.  Data presented were obtained from triplicate assays.  Data points represent 
means±SD. 
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5.6 Role of HMGN3 in NF-B and p38 pathways 
TNFα induces the NF-B and p38 (Beyaert et al, 1996) signalling pathways.  The 
mCCL1 gene contains an inducible NF-B element at position -194 to -185, 
relative to the TSS.  To investigate whether HMGN3 affects either the NF-B or 
p38 signalling pathways, Dual-Luciferase Reporter Assays were performed as 
described in Section 4.6.  NF-B or p38 reporter plasmids were incubated with 
cells for 24 hours to allow transfection.  Activation of the NF-B and p38 
pathways leads to expression of the luciferase reporter gene which can be 
quantified. 
5.6.1 NF-B plasmids 
The NF-B reporter plasmid (pNF-B-Luc) contains direct repeats of the NF-B 
transcription factor recognition sequence.  This controls expression of the cis-
reporter Photinus pyralis (firefly) luciferase gene which can be measured using a 
luminometer.  The NF-B negative control plasmid (pCIS-CK) contains the 
luciferase reporter gene but lacks the NF-B DNA elements, while the positive 
control plasmid (pFC-MEKK) contains a kinase that is constitutively expressed 
and activates transcription of the luciferase gene. 
5.6.2 p38 plasmids 
The p38 system requires transfection of two plasmids.  The reporter plasmid 
(pFR-Luc) contains five tandem repeats of the yeast GAL4 binding sites that 
control expression of the cis-reporter Photinus pyralis (firefly) luciferase gene.  
The Fusion Trans-Activator plasmid (pFA2-CHOP) expresses a fusion protein 
containing the activation domain of CHOP fused with the GAL4 DNA binding 
domain.  CHOP is a transcription factor that is activated following p38 
activation, which occurs following TNFα stimulation.  The Fusion Trans-Activator 
negative control plasmid (pFC-dbd) contains the DNA-binding domain of yeast 
GAL4 but lacks the activation domain, while the positive control plasmid (pFC-
MEK3) constitutively expresses the MEK3 kinase (Mitogen-activated protein 
kinase 3) which phosphorylates and activates p38. 
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5.6.3 Optimisation of plasmid ratios 
The transfection conditions for the plasmids were first optimised.  pRL-TK, 
which constitutively expresses Renilla (Renilla reniformis) luciferase, was used 
as a transfection control.  T23 cells were transfected with the plasmids then 
treated with TNFα.  The Dual-Luciferase® Reporter Assay (Promega) was used to 
quantify expression of both firefly and Renilla luciferase.  An optimal pNF-B-
Luc to pRL-TK ratio was determined by altering both the quantity and ratio of 
the plasmids (Figure 9A).  An optimal pNF-B-Luc to pRL-TK ratio of 20:1, using 
0.04 µg pNF-B-Luc to 0.002 µg pRL-TK, was chosen as this yielded the greatest 
induction of luciferase expression (Figure 9A, indicated by black arrow).  A cell 
density of 2.2 x 104 per well and an incubation time of 24 hours yielded the 
optimal increase in luciferase expression (Figure 9A, indicated by black arrow). 
To maintain continuity, the same cell density, incubation time and quantity of 
pRL-TK was used for p38 transfections.  The optimal quantity of pFR-Luc to 
pFA2-CHOP was found to be 0.04 µg to 1 ng (Figure 9B, indicated by black 
arrow). 
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A 0.04 0.05 
B 0.04 0.2 
C 0.04 1 
D 0.04 4  
Figure 9  Optimisation of plasmid ratios and quantities. 
The Dual Luciferase Assay was carried out as described in Material and Methods Section 4.6.  
The plasmid ratios and quantities are shown in the tables below the graphs.  Cell densities of 
either 2.2 x 104 cells or 1.67 x 104 cells were investigated.  Plasmids were incubated with 
T23 cells for 24 hours to allow transfection.  Cells were treated with 0.05 µg/µl of TNFα for 
either 24 hours or 5 hours, then all assays were analysed using the luminometer.  Data 
points represent mean and standard deviation of quadruplicate assays.  Subsequent 
conditions used are indicated by black arrows. 
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5.7 NF-B luciferase results 
To identify whether HMGN3 affects the NF-B signalling pathway, T23 cells 
grown in the presence or absence of Dox were incubated with plasmids for 24 
hours (Materials and Methods Section 4.6.1).  Cells were then incubated with 
0.05 μg/μl TNFα for 24 hours to allow luciferase expression, before luciferase 
expression was quantified using the Dual-Luciferase® Reporter Assay. 
Following TNFα treatment, NF-B-dependent luciferase expression increased 6-
fold in cells uninduced for HMGN3, and 4-fold in HMGN3 induced cells (Figure 
10A).  Similar results were obtained from repeating this experiment twice more.  
A Student’s t-test was performed to determine whether the difference is 
statistically significant.  For each experiment, HMGN3 was shown not to have a 
statistical significant role in affecting the NF-B signalling pathway, although a 
near statistical significance (p = 0.0571) was obtained for the data presented 
(Figure 10A). 
5.8 p38 luciferase results 
Similarly, to identify whether HMGN3 affects the p38 signalling pathway, 
luciferase assays were carried out as described previously.   
Following TNFα treatment, both HMGN3 induced and uninduced cells had a 1.6-
fold increase in p38-dependent luciferase expression (Figure 10B).  Repeating 
this experiment twice more produced similar results.  Performing a Student’s t-
test showed no statistically significant difference in luciferase expression.  It is 
worth noting luciferase expression was low in cells transfected with the positive 
control pFC-MEK3 (1.4-1.8-fold, Figure 10B), and low in the optimisation assays 
too (Figure 9B).  This suggests the p38 signalling pathway is not very active in 
T23 MEF cells and is not highly induced following TNFα stimulation. 
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Figure 10  Luciferase assays study the effect of HMGN3 on NF-B and p38 signalling.   
Luciferase assays were carried out as described in Material and Methods Section 4.6.  Cells 
plated at a density of 2.2 x 104 cells were incubated with the appropriate plasmids for 24 
hours to allow transfection.  Cells were then incubated with or without 0.05 µg/µl TNFα for 
24 hours.  Results are normalised to cells uninduced with TNFα.  (A)  A pNF-B-Luc to pRL-TK 
ratio of 20:1 was used, using 0.04 µg pNF-B-Luc to 0.002 µg pRL-TK.  In addition, the 
positive control plasmid (pFC-MEKK) indicated the reporter system was working (data not 
shown).  (B)  0.04 µg pFR-Luc and 1 ng of pFA2-CHOP were used, along with 0.002 µg pRL-
TK.  The data shown are representative of three independent experiments.  The data 
represents mean and standard deviation of triplicate assays. (A) (p=0.0571).  (B) (p=0.9223) 
Craig S Davis, 2008  Chapter 5, 75 
5.9 Summary of HMGN3 in NF-B and p38 signalling 
In conclusion, following TNFα stimulation the NF-B pathway is induced in T23 
MEF cells, however, HMGN3 does not have a statistically significant role in 
altering NF-B signalling.  TNFα stimulation leads to a modest increase in p38 
signalling, however, HMGN3 does not significantly alter p38 signalling. 
 
Craig S Davis, 2008  76 
6 Discussion 
HMGN proteins bind to nucleosomes and modulate chromatin structure.  These 
proteins reduce the compactness of the chromatin fibre and enhance 
accessibility to nucleosomes overall, but they also alter the accessibility of 
residues on the nucleosomes they bind (Ding et al., 1997).  HMGN proteins 
modulate histone modifications, such that HMGN1 and HMGN2 enhance 
acetylation of Histone H3 lysine 14, while HMGN1 inhibits phosphorylation of 
Histone H3 serine 10 and serine 28 (Lim et al., 2004; Ueda et al., 2006).  As a 
result, HMGN proteins are important in modulating transcription and replication 
(Bustin, 2001).  Although HMGN proteins reduce the compactness of chromatin 
and improve access of transcriptional activators, this will also improve access for 
transcriptional repressors. 
HMGN3 is unique amongst the HMGN family as two splice variants are produced 
from the HMGN3 transcript (West et al., 2001).  Unlike HMGN3a, HMGN3b lacks 
most of the CHUD, although the functional consequences of this require further 
investigation.  Both HMGN3a and HMGN3b bind to the promoter region of the 
Glyt1 gene and up-regulate expression of Glyt1 (West et al., 2004b). 
Previously, HMGN3 was shown to reduce the level of TNFα-induced expression of 
the murine chemokine gene CCL1.  The aim of this investigation was to 
determine the role of HMGN3 in regulating gene expression by studying the 
mouse cytokine gene CCL1.  The mRNA data confirms HMGN3 reduces the level 
of TNFα-induced mCCL1 expression.  The ChIP results presented here show 
HMGN3 binds across the mCCL1 gene, and HMGN3 binding correlates with 
H3K14ac.  Peaks in H3K14ac coincide with peaks of HMGN3 binding at the mCCL1 
gene.  TNFα stimulation leads to decreased HMGN3 binding and this correlates 
with reduced H3K14ac at the mCCL1 gene.  This is reminiscent of a previous 
study that showed HMGN1 inhibits anisomycin-stimulated fosB transcription (Lim 
et al., 2004).  Taken together, this shows that HMGN3 fine-tunes TNFα-induced 
gene expression, and suggests it may be necessary to remove HMGN3 from the 
mCCL1 gene in order to get efficient transcription. 
The mCCL1 gene contains an inducible NF-B element.  TNFα stimulates the NF-
B and p38 signalling pathways.  An important step in NF-B activation is 
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phosphorylation of IB by IKK, as this allows NF-B to translocate from the 
cytoplasm into the nucleus where it can bind to the NF-B element and activate 
transcription (Figure 4).  IKK consists of two kinases, IKKα and IKKβ, and a 
regulatory subunit IKKγ.  IKKβ and IKKγ are critical for cytokine induced IkB 
degradation.  IKKα, however, can directly phosphorylate H3S10 and enhance 
acetylation of H3K14 at NF-B regulated promoters (Anest et al., 2003; 
Yamamoto et al., 2003).  Phosphorylation of H3S10 seems to be important for 
the subsequent acetylation of H3K14 by CBP (Yamamoto et al., 2004).  p38 also 
induces phosphorylation of H3S10, which may improve access for NF-B to bind 
the NF-B site (Saccani et al., 2002). 
To gain insight into whether HMGN3 affects mCCL1 gene expression through 
either the NF-B or the p38 signalling pathways, luciferase assays were 
performed.  HMGN3 was shown not to have a statistically significant role in 
either the NF-B or p38 signalling pathways, although HMGN3 was shown 
statistically to have a near significant role (p = 0.0571) in the NF-B signalling 
pathway. 
As just mentioned, HMGN1 mediates transcription from the fosB gene, whereby 
following stimulation, HMGN1 bound at the fosB gene is phosphorylated by MSK1, 
reducing HMGN1 binding to chromatin, and enhancing the accessibility of MSKs 
to phosphorylate H3S10 (Lim et al., 2004).  HMGN3 may participate by a similar 
mechanism.  HMGN3 binds mCCL1 chromatin, enhances H3K14ac as shown by 
ChIP, and may inhibit TNFα-induced H3S10 phosphorylation, possibly mediated 
by IKKα, inhibiting mCCL1 expression as shown by RNA data.  However, following 
TNFα stimulation, HMGN3 may become phosphorylated, possibly by IKKα or 
MSK1, reducing HMGN3 binding to chromatin as suggested by the ChIP results, 
enhancing the accessibility of H3S10 phosphorylation, possibly by IKKα (Figure 
11).  The reduced binding of HMGN3 may be necessary for efficient expression of 
the mCCL1 gene. 
Enhanced H3K14ac mediated by HMGN3 is gene specific, as H3K14ac levels were 
unaffected by increased HMGN3 enrichment at the Glyt1 gene. 
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Figure 11  Reduced HMGN3 binding to nucleosomes enhances H3S10 phosphorylation. 
Prior to TNFα stimulation, IKKα is in the IKK complex and HMGN3 binds to nucleosomes at the 
mCCL1 gene, inhibiting transcription.  TNFα stimulation leads to the activation of the NF-B 
pathway, IKKα translocates into the nucleus, HMGN3 becomes phosphorylated weakening its 
interaction with the nucleosome, allowing IKKα to phosphorylate H3S10 and initiate 
transcription.  As the magnitude of the stimulus recedes, nuclear IKKα levels decrease, 
HMGN3 is de-phosphorylated favouring re-association with the nucleosome, eventually 
restoring transcriptional repression.  Acetylated, red circles; Phosphorylated, green circles. 
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6.1 Further work 
To investigate whether H3S10 becomes phosphorylated following TNFα 
stimulation, Western analysis of cells incubated with or without TNFα should be 
carried out.  If H3S10 becomes phosphorylated, whether this modification occurs 
at the mCCL1 gene can be investigated by ChIP assays, using chromatin from 
cells incubated with or without TNFα.  As IKKα can phosphorylate H3S10 treating 
cells with IKKα inhibitors would reveal whether this kinase is responsible for 
H3S10ph following TNFα stimulation. 
HMGN proteins regulate gene expression by mediating access of histone 
modifying enzymes to their nucleosomal targets.  These enzymes not only target 
histone tails, but also HMGN proteins.  p300, a histone acetyltransferase, also 
acetylates HMGN1 and HMGN2 at multiple sites, weakening HMGN binding to the 
nucleosome, thus improving access of p300 to induce histone changes (Bergel et 
al., 2000).  PCAF, also a histone acetyltransferase, can also acetylate HMGN2 
which reduces the affinity of HMGN2 for nucleosomes (Herrera et al., 1999).  
MSK1 and RSK2, two kinases known to phosphorylate H3S10 and H3S28, also 
efficiently phosphorylate HMGN1 which precedes histone phosphorylation (Lim et 
al, 2004).  As IKKα can phosphorylate H3S10, IKKα is a key candidate as the 
potential kinase for phosphorylation of HMGN3.  Western analysis of HMGN3 will 
show whether HMGN3 becomes phosphorylated following TNFα stimulation, and 
identify the residues targeted. 
If, following TNFα stimulation H3S10 becomes phosphorylated, ChIP assays or 
Western analysis for H3S10ph will show whether HMGN3 inhibits H3S10ph as 
suggested here.  Further investigation will show whether TNFα induces other 
histone modifications at the mCCL1 gene, such as H3K4me3 and H3K4me, which 
are found at active promoters and enhancers respectively (Heintzmann et al., 
2007).  In contrast, H3K27me negatively regulates transcription (Martin and 
Zhang, 2005).  ChIP assays would then show whether these modifications are 
affected by HMGN3. 
In addition to H3S10ph, H3K14ac and H3S28ph, HMGN proteins also affect 
H3K9me, H3K9ac (Lim et al., 2004) and H2AS1ph (Postnikov et al., 2006).  
Further investigation will show whether combinations of histone modifications 
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are induced by TNFα, such as H3S10p with H3K9ac or H3S10ph with H3K14ac, 
and whether these are affected by HMGN3.  As a result, knowledge of the 
relationship between HMGN3 and gene expression will be improved. 
Further ChIP assays will establish a higher resolution map of HMGN3 binding, and 
for the associated histone modification H3K14ac across the mCCL1 gene.  From 
the results obtained, higher levels of H3K14 acetylation occur 5 kb upstream of 
the mCCL1 TSS.  High levels of H3K14ac are found within the 700 bp region 
extending upstream from the TSS.  This region has been shown to enhance 
mCCL1 expression (Oh and Metcalfe, 1994).  A lower level of H3K14ac is 
observed at primer set H which lies at the negative regulatory element-2b.  
Further investigation is required to see if these trends continue across the 
regions associated with transcriptional enhancement (1342bp upstream from the 
TSS) and repression (between 1342 to 2057bp upstream of TSS). 
In summary, HMGN3 binds mCCL1 chromatin and enhances H3K14ac.  HMGN3 
may hinder the accessibility of kinases, such as IKKα, to H3S10 in nucleosomes, 
and thus inhibit induction of transcription.  On this basis, HMGN3 functions 
similarly to HMGN1 at the fosB gene, where HMGN1 enhances H3K14ac and 
hinders phosphorylation of H3S10, reducing gene induction in response to 
anisomycin. 
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 8 Appendix I 
Nucleotide sequence for mCCL1 gene, including flanking regions.  Numbers to left of sequence are relative to TSS.  Location of     
regulatory sites and exons shown to right of sequence and highlighted in colour in sequence.  Location of forward and reverse primers     
“A, H, I, K, O and T” are shown to right of sequence and underlined in sequence.  1st number in bracket after primer indicates primer  
name in Table 1, 2nd number corresponds to primer location relative to TSS in the sequence shown. 
Mus musculus (lab mouse) (Build 37.1) 
Chromosome 11 Minus Strand From:  81988137  To:  81998296 
Contig: NT_096135.5  Start: 47493015  Stop:47503174  Strand: Minus  
       
     -5000 gggccttcaa gactacgcat gatggaaggc atgccttgtc ctgagtaaac catggtgaca Primer “A”(0002F, -4973) 
     -4940 atcagcaggg atgaacgagc cttgtcaaca taatcttgtg taacccgact tgggcctctc Primer “A”(0054R, -4921) 
     -4880 cctattcatt tttagagccc gcctccacac ttgtgcttga cctcactgct cccattttcc 
     -4820 ttgagaactc tgccaggcat tgttctgagc atattcctcc aacgccatac caagcctata 
     -4760 agcagcgggt attcacatat ccatttagag atgagctcag agctgaagca ttcaaaggag 
     -4700 cctggactgg cagcctacag gttggcccag aacctgctca aaaccactac catggtagct 
     -4640 ccacacattc ttcccctctg ggtacaccct gcttgcatcc ttccaggcct aggtgaaata 
     -4580 ccacactgct acctaaggag cccttagcct ctagaccata cactaatgac agcctgtgtc 
     -4520 cagctgttgt tttgtgggtg ctctttcccc taaatctggc cctggagggc agatctgagc 
     -4460 tatgatccct tctcttgcct cagtacccag gcacgaactg ctaaacagcg ggtctctgga 
     -4400 agatgcctac agagagaata gaggagcatc ccactaaacc atagctgtcc cagggacccc 
     -4340 acacttaata tgttgtccac acagaaattg caagatttcc agcagtggaa ctctgtataa 
     -4280 acagatgtag tttcagaacc cagttactta ttctgggttc caaataagta actggtcacc 
     -4220 tgtgtgctca ctatcacctc ctgactgccc actaaggttt gaggcctcag tgggtacaaa 
     -4160 cttctttctt cttatttcca gtagtagctg catcccacat acagatggca aagagaggtc 
     -4100 tgactgggag agaaagagtt ctgctctcta gagctcctgg agagggtggg acatggaacc 
     -4040 ctagggaacc aaaacctgca gttgctggtt ctctccagga gctcggggtg gcacagcctg 
     -3980 tgcagagttg gtcatgtgaa gccaggggaa ggttctgagc aggagaagca gaaggcctga 
     -3920 catctgaaga gaaggacttc agtgagcagg gccgtcactt cacactttgt aagtgcggcc 
     -3840 aagacatttg tactttcacc ctgagcacag cgggctggcc tttcaggctc agaagcactt 
     -3780 gaaagaacca gtgatggtca ctattgtgac aacctctgcc tgcttctatt gtagtgagag 







     -3660 acaaagcagc taaaaaacca caggaacagg aagtaaagaa gccagggctc agggctcagg 
     -3600 attctgtggt gtgtgggtgc tgggcatctt tactgtgaat agacataggc ttacctcagg 
     -3540 caactgtgtc tggggcagat atcaaggacc cagaaggaca ctgtgaccac atcgttaaag 
     -3480 acacatcatt aaggacacct gggtgtctgt agaccaggct agtagcaaaa gagactgggt 
     -3420 agtagagccc tgtttgggag acagtgacac atcttggtgt cacccgtgga cctctcagag 
     -3360 cagtcccaga tctggagcaa aggggaccca gttttagggg tggatccagt gacttctgca 
     -3300 gccctcccca ccaggacacc gtctcttctg gagcccgtcc tatatttaaa ccactcccca 
     -3240 agatctacct ctgcataatc tgggagtccc cctgagattc acttggttcc ccctagtact 
     -3180 tctcctggag attctttcct ttcctctcaa gccagctcct atcacaggga gccctcccaa 
     -3120 caacccacaa ttaggctaag gcttaggaag tttattttga cagtactaaa gagagttgtg 
     -3060 cttggtccaa gaggaaacac agctcagaaa gcctgtatta cctgtccagg atgaagcggt 
     -3000 agaactagga tctgatgtgt ctatgtctgg ctctagtcac tgttcctctt cctctccctg 
     -2940 aaggaataca tagagaattt cactctggag atggatcaag tcatctctgc agctctgcca 
     -2880 tgctcaacac atgccaaggg gctggccgtg gcctgctatg gaaggaccac ctgacctgta 
     -2820 actcagtagc aggtggtaga cagggctggg ctgaatgcct ctggacagca tcttaggatg 
     -2760 actccaccct ggctgccagc cacctgatcc ccgtcctcat tcagtggtcc ctagaaaatg 
     -2700 aaagatgagt gacaagggct cctaactaca cgccacagaa agaaggcttg cttgtgtgaa 
     -2640 tgataacagt gcgtatcccg aggtcacctc ttgtttgcca atccacgatc atttctgctt 
     -2580 gctcatttcc acagaggctt tattgaccta tcacatggtc ctagtccctg ggcctcgaca 
     -2520 gccatgttgg ggtacccatg tgtaatatga agttgctgga tgataaatcc tacttttggt 
     -2460 cacttctttc caggtgctga gagagcccag gaaggtaagg cataacaaag tactaatgag 
     -2400 ttcctctttt ctgtttggga aatactgtgg tcacagtgag ggggaagatg gggagctagt 
     -2340 tgttgaggga cagctcccag aacaggggaa gaaccagaaa tttccagggc agctatgtgg 
     -2280 ccccttcttc actgcccgag tctaaagggt ctatacttgc atttggccag tttttatata 
     -2220 ctcacatctc ccctttccca agaccccggg ggtaaaggac cagaacacat cagcctccaa 
     -2160 agacaaggac atagagaggc agcaatgggg tagtaatttt aatgactttg tgggtggcag 
     -2100 gaagcagtag gggtctgact ggcatgggtc cagctgtgta aagatcatga gctgatctta 
     -2040 ttcttagata cccagggctc gagtctctgc ctcctatgcc acccccattc tcaatatagc NRE-1a (-1999:-1990) 
     -1980 atcaagccca agacttccct cctcgtgaaa gtcaccctcc caccctccat actgtggaga 
     -1920 ttttatctct tggtgctttg acaattgcct ggagttttct cctcacaagt acaggcactt 
     -1860 gagttttgat tctgactctg aaatggagcc aagatattcc cagtttcgac aaagctccct 
     -1800 caggagtgcc aagagtcatc actgccaaag gtcttgaaaa gctcattcag ctcagacatg 
     -1740 ccacggtagc acggagcgag cctcagtgga gagatgcggg aagacaagga cttccgattg 
     -1680 ccatccaggc acaggggctt aaaggaggct gagatttgcc cgcaggggtt ggcaaatgac 
     -1620 ttttattgga ggaagggtgt ttgaaatgag cagattgggc acagagggag ttggctggga 
     -1560 aggtggtcag gtcgatgtta cagtaaggat gagatggtgg atataggaga gcaaaatgga 
     -1500 tgactgaagc ttgactattt gggaagagtt ctaactatct agtagttaca ctcagttggc 
 







     -1380 acccactgtg tataggcccc atgatgccaa tgccagaaag cttagctgct ttttcttgag Primer “H”(3598F, -1357) 
     -1320 ggcctcctat gagctgctta tcccaagtac tgcccactgc atatactgtt tttatctggc Primer “H”(3648R, -1307) 
     -1260 tgcacaaccc catctgcatc tacatcccat gctctagctt tctccatgat gctgagtgaa 
     -1200 gggtgttcct ctgtacttgg cttttccaga ctccttcccc tgcctgacgt gctgtcttca 
     -1140 cagcagcctg caggacatgg tacttataga acactgtctg gaaagggtcc tctgaagtcc 
     -1080 ctgggtgtcc ccaacattct cctgtgcccc ccacatgaca gatctgtctt gaatgagccg 
     -1020 ttgttgtgtt ggatggctct ccatggcttg tctataggtt gaagcaagat ggctcaggtc 
     -960  aggctttgcc cccattggca attgtcccaa gggtaaccaa gcaagggtct ggatcagagt 
     -900  aagctgtgaa agggctgggg aacaaagaaa taaaactaat agcaaatgtg ttggccaaac 
     -840  gttagacaga caggatcaac ctgtggtatg tgtgtgtatg tgtgtgtgtg tgtgtgtgta 
     -780  catgtatgta ggtgtgcata catgtgtcta tgtgcatgtg aacgactttg ctttttgaga 
     -720  taagttctct ccctggcctg gaggtctcca actaggctca gcgggcaaac caggcagctc Primer “I” (4265F, -690) 
     -660  cagggatcag ccggtcagcc tctccagctc tggggttaca agatcattcc actacccctg Primer “I” (4345R, -610) 
     -600  ctctgtatgc gggttctggg aatcaaactc tggtcctcac acttgtgtag caggtacttt 
     -540  gctgactgag ccatctcccc agctctgcat ttcattctta ccacccggat ttgagatgtg 
     -480  ttactagttc cattttgtag ggatgtgcag cttagagaag tttgtgcaat ggctgattgg 
     -420  cagagccaga acccagacac aagctccatt tgatgcagat tgtaccttct ctgctctgtc 
     -360  cttctccaag gcctgtagct gctttgaatg gaatgatgtg ggttagacaa gctgtgtacg 
     -300  ggccacttcc tctctctctc tcaccttttt tgactttcca ctcagccagg acagctccca 
     -240  cgtattttgt caagaacgta aagattggta tctgcttctg cacttgggga agttcccaag NF-B (-194:-185) 
     -180  gccactaggc acccaaacat acctcgaata cgcccccctc ctcccaggag aggtgagaaa 
     -120  aggagttttc catgtggcca ttgggtatga gttccttttc cctgggactc ccacctcttc Primer “K” (4850F, -105; 4900R, -55)  
     -60   tccatggtct gggaaagcac cccgggcctt ctgataaaag ctcagtacag ggtgaggcag TATA (-29:-23) 
     +1    gagagagttc ttggctccac cagacattcg gcggttgctc tagagaggct tgagacagaa EXON 1 Transcription start site (1:146) 
     61    acttatcacc atgaaaccca ctgccatggc actgatgtgc ctgctgctgg ctgccgtgtg Translation start site (71:73) 
     121   gatacaggat gttgacagca agagcagtga gtaatggggt cctagtgctt gggcccaggg 
     181   aggggagatg tataggcagg cactctgggc tgggaacaga gcttacctag acatcattgg 
     241   cttcatttct gtccctatct ggagatgaat ggcgggcagt aatgggatag ggacgctggg 
     301   cgtggaggaa ggttatggac tgggagcaca catctacttc gtggtgggga gctcagacct 
     361   gaaacccatt cctctgattc ttttgctaat cctagaacta ggtggctgca gagacagacc 
     421   tgggccagca tcctcttgat ggggttccaa gactggccct gttctgggag gagcttctcc 
     481   ttctccttct ccttctcctt ctccttctcc ttctccttct ccttctcctt ctccttctcc 
     541   ttctccttct ccttctcctt ctcctccttt ctcccttctc ctttctcttc ctcctcatcc 
     601   tcctttctcc cttctccctt ctcccttctc ctttctcctt tctcctttct cctttctcct 
     661   cctcctcctc ctcctcctcc tcttcatcct cctccttcta gatgaagtgg ctttagtgtg 
     721   tggaagataa ttttgatcct caccctacag acaactggaa gggcctatgg ggttgtttaa 
     781   aacaaattag gatccctgaa gtccagagga gggactaaga ctgatttcca gtgtgacaga 
 







     901   cttaaagatg ttttctgtat ggataaactg gaatccatgt tctagattgt tcggaaaata 
     961   ccaacctgag gtcaggggac ctgcaagttt ctgtgaacag cgagacagga aggatccagg 
     1021  gttagaacac agggatgttg aaggtgggat gtgggaggag agcgtacaaa tcagcagact 
     1081  gggggttact ggtccctgaa agaggggagg gccaaggatg ggaatgtgga agattgtgtg 
     1141  ggcgagtgga ccagccactt tttgggaata cccccttttc cttctgagcc cttgtggagt 
     1201  tcctcaccca gccccatgtc tgtgaaccaa gaactacaat gtcctgcatg cgatgggata 
     1261  acaggtcctc taggatgtga ggccagagcc ccgagcttaa gtactagcac agtacacaga 
     1321  gccacgcact tgtgctggga gactgggact gaaggggttt gtatatgtgg taggaagagt 
     1281  ctcaccgtat gtgcaggagt gtgtgctgag ccatggctca ggcaggcttg tggtttctgt 
     1341  ccccaccacc tgctggtttg tagggtgctc acatctgacg cccctcccca gtcttatgat 
     1401  tgttgtctcc atcctagaaa tgtgttgctg ctgagacaga gctgcactgc agccctcggg 
     1461  atgtggtctc catgcttgag tctgtcctag gaaggacttg gctggttttg ctttttaatt 
     1521  ctgttgtggg tgagaggcta tggttgctaa tgaatggtct ttttttgtgc ttttcttcta 
     1581  gtgcttacgg tctccaatag ctgctgcttg aacaccttga agaaagagct tcccctgaag EXON 2 (1582:1696) 
     1641  tttatccagt gttacagaaa gatgggctcc tcctgtcctg atcccccagc tgtggtgtga 
     1701  gtgagccact agccagggga gagataatat tgacggaatt gagaatagta cacactagat 
     1761  ggcgctgttc cacaagaaaa gggagtctaa acccaaccag gcaatctaag gtgtagagtg 
     1821  acactagggg gcgtggggct tcccaggaag gggggggggg tcctgattta tttgcttgaa 
     1881  ccccaaagtg cctatgatta gatcccaagc tatatagcca ggaagaaatg tttaataaaa 
     1941  gcacaacaga caaggctgga gcgttggctc agtgggtagt ttggctgctc aaacacggtg 
     2001  atttgagttc atattcccag caggatggtg tgagtttgta accccagtgc tagatgaggc Primer “O” (7070F, 2016; 7121R, 2067) 
     2061  agaggcaggc atagcctgtg tgcttgctgg ccctaacaaa gttctgtggg agatcttacc 
     2121  tcgaaatgta ggacaaacaa tccactaagg aagatttcat aaccaccgac ccctggccac 
     2181  cacacatgtc tatataccat gaaacacaca cacacacaca cacacacaca cacacacaca 
     2241  cacacacaca cacactatac aaacacacac accacatata catatcacac acaccacaca 
     2301  aacacacacc acccactaca caaacacaca taccacaccc cccacataca tccccacata 
     2361  caccccctat atcacagaaa cacacatacc acactaacac acacacatac cccacacatc 
     2421  tcagacccta caaacacaca cacacacaca cacacacaca cacacacaca cacacacagt 
     2481  aggccccagg cagacacaca aatattcaaa cctggagcaa ggagttgttc taggattggg 
     2541  acgtttcgtc ctagctacac atcagactgt ccgccagctc ctgtgctctg taccacaaag 
     2601  ggaattctag tctccacggt aggcttcagg ggtccccatt aataagcttc caatgtaaca 
     2661  caggcacgcc agcttcagat cttgtaaaat ttcttcattt acagagtcag gagttcaggg 
     2721  gtccctggtc tcacagaagc agagaagact gttacagatt ccagtgagtg accaaggtcc 
     2781  ttgtccgtgt cttctgttca cagattcagg ctgaacaaag gtagagaaag ctgcgcctca EXON 3 (2804:3049) 
     2841  actaacaaaa cgtgggttca aaatcacctg aagaaggtga acccctgcta accggggtga 
     2901  agatgagcca ccttcccatc ccagcaccag agactgcagt ttccctcagt cctccaccct 
     2961  cccactgccg ccacccctac tgctgcaggc tcacagacct cagtcatgtg ataagctatg 
 







     3081  gactccatga cgatttcaga attcagactt gattggcact ggggtgggaa cacgggctgg 
     3041  aaagttgagc tggtgctgtg ggaaccactg tataggataa gttttgatcc cggctgtgca 
     3101  atggtcttta gtagccaaag gagccactgt agaataacca actgtcccag agcagggttc 
     3161  acattgagat gagagccctt cttcttgcct gccctgccca aagtacttgg gagtggcaat 
     3221  gctagcctat tgttagctgg aagggatctt tgtgttcatt tgcctgtaag atgttgccaa 
     3281  ccttgtttta taaatgaagt aagtgatcgg ggttggagaa ggacacagaa tgttagggcc 
     3341  aaagagccag gccaggggaa ggcatgaaaa ggcttagagg tgtgtagcag acccaggaaa 
     3401  gagcctttgg gcataagtgg gaggctctag ggaaaggagt agcagatggc agaagcctgg 
     3461  tatgaagcaa ggatcgtaag ccagagaagt aggcattaga ggcactgttc tgggcactca 
     3521  caagagccca agccagccaa cagttagact ctgaagatca ttttccttcc tccatattcc 
     3581  acgaccctcc tgaccctcta atggccaaga gctatccctg aagaaaatgc agtttctgca 
     3641  aaccaccagg ggtcctccta ttgtgcccat cctcctattt gcctgcttcg aaatctcacc 
     3701  ctcataatgt aggccaatcc ctgggacaca gtgtccttct acctttcctg cagggacaca 
     3761  gttcaaccct gcaagctgga tagaaaccta ctcaggttac aaagggcagg cagggcctgg 
     3821  ggttcatgtg gtcaagaacc aactttcttt agactttgct taaaaaaaaa aatcagggct 
     3881  gggaggcttg tagagatggt ttagtggtta agagcaccac atgctcttcc agaggactca 
     3941  ggttcgattc ccagcattca catggcagct cacaactgtc tgtaactcca gttccagagg 
     4001  atccaacacc atcacacagg catatgcagg caaaacacca gtgcacatga aagaaaaata 
     4061  aataaataaa atcagtggag ctgagggtgc aatttgatgg ctgaacattt gttcagcatg 
     4121  cacaaaccac aatgttgaaa gtccagcacc ataaagacac aataaaaata gattattagt 
     4181  attcaaaata caacccaaac cactgagaat tcaaatgcag tatcaccgaa ggcatgatgt 
     4241  gttttgtatg aaaaacagtc aagttattcc agagtgtaga tggtaaggct gagaggagag 
     4301  caaaattgct accttgaata gtcttgcagg ctctaagtat gagcagtaga gcgaaggtcc 
     4361  tggagggtga ggctttggtc cgggtgtggc acggtgtctg ggacctttgc ctgaggtagg 
     4421  cacagagctc accggctaaa gagcattgga tgctgctgat ggtggagagc tgcaattaga 
     4481  agacccctgg aaccggttca ctcactcttt ctctctgcct ggctcaccaa cgtggtgtgt 
     4541  gggaaagggg gacctctaga ggcagctgtt tctctgctgt gtgactcagc aaaaatctac 
     4601  ctggtagctg atgaatgcca ggatgtgaag agactgcagc cactagaggg cagggcactt Primer “T” (9775F, 4621 ; 9831R, 4677) 
     4661  gtgggaagtt gccaagcctc tcctgggcac ttctgtacta caagaatgtg gagactttga 
     4721  cattatctcc ccagcctcag gctccaggcc atctggcatc tatgttctga ggcaaagctt 
     4801  acacaggaca gtgtattagt aagggttccc tagagtcaca gaacttatgg aatgtctata 
     4861  tattaaggaa atttattgta atggcttaca gtctgcagtc taactaacca aacaatgggc 
     4921  agctgtgagg aaagtccaag aatctagttg ctcagttcta caatcctagt agtttcagct 
     4981  ggtcttctgt ataagctggg // 
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